SGLT2 INHIBITION FOR LIFESPAN EXTENSION

/ HALLMARKS OF AGING, SCIENCE, SOLUTIONS / By
  1. SGLT inhibitors in management of diabetes
  2. Structural selectivity of human SGLT inhibitors
  3. A novel approach to control hyperglycemia in type 2 diabetes: Sodium glucose co-transport (SGLT) inhibitors. Systematic review and meta-analysis of randomized …
  4. SGLT inhibitors as antidiabetic agents: a comprehensive review
  5. International consensus on risk management of diabetic ketoacidosis in patients with type 1 diabetes treated with sodium–glucose cotransporter (SGLT) inhibitors
  6. SGLT inhibitors in type 1 diabetes: weighing efficacy and side effects
  7. SGLT inhibitors for type 1 diabetes: proceed with extreme caution
  8. SGLT inhibitors attenuate NO-dependent vascular relaxation in the pulmonary artery but not in the coronary artery
  9. Strategy for mitigating DKA risk in patients with type 1 diabetes on adjunctive treatment with SGLT inhibitors: a STICH protocol
  10. SGLT inhibitors for type 1 diabetes: an obvious choice or too good to be true?
  11. The anti-inflammatory effects of SGLT inhibitors
  12. Na+-Glucose Cotransporter (SGLT) inhibitors as Antidiabetic Agents. 4. Synthesis and Pharmacological Properties of 4′-Dehydroxyphlorizin Derivatives Substituted …
  13. SGLT inhibitors as new therapeutic tools in the treatment of diabetes
  14. natural products as lead compounds for sodium glucose cotransporter (SGLT) inhibitors
  15. SGLT inhibitors for people with type 1 diabetes
  16. SGLT inhibitors: a novel target for diabetes
  17. Impact of SGLT inhibitors on Multiple Organ Defects in Diabetes.
  18. Effects of sodium‐glucose cotransporter (SGLT) inhibitors in addition to insulin therapy on glucose control and safety outcomes in adults with type 1 diabetes: a meta …
  19. Pyrazole-O-glucosides as novel Na+-glucose cotransporter (SGLT) inhibitors
  20. Synthesis of isotopically labelled SGLT inhibitors and their metabolites
  21. Cyclic diarylheptanoids as Na+-glucose cotransporter (SGLT) inhibitors from Acer nikoense
  22. A quantitative systems pharmacology kidney model of diabetes associated renal hyperfiltration and the effects of SGLT inhibitors
  23. QSAR studies on triazole derivatives as SGLT inhibitors via CoMFA and CoMSIA
  24. Diabetic proximal tubulopathy: Can we mimic the disease for in vitro screening of SGLT inhibitors?
  25. The bark giving diabetes therapy some bite: the SGLT inhibitors
  26. Effect of SGLT inhibitors on weight and lipid metabolism at 24 weeks of treatment in patients with diabetes mellitus: A systematic review and network meta …
  27. Synthesis of L-rhamnose derived chiral bicyclic triazoles as novel sodium-glucose transporter (SGLT) inhibitors
  28. SGLT inhibitors and euglycaemic diabetic ketoacidosis: earlier observations rediscovered
  29. Commentary: SGLT inhibitors in type 1 diabetes: Place in therapy and a risk mitigation strategy for preventing diabetic ketoacidosis‐the STOP DKA protocol
  30. Synthesis of novel l-rhamnose derived acyclic C-nucleosides with substituted 1, 2, 3-triazole core as potent sodium-glucose co-transporter (SGLT) inhibitors
  31. SGLT inhibitors for type 1 diabetes
  32. Factors that predict glycaemic response to sodium‐glucose linked transporter (SGLT) inhibitors
  33. The bark giving diabetes therapy some bite: the SGLT inhibitors
  34. SGLT inhibitors attenuate NO‐dependent vascular relaxation in mouse pulmonary artery (677.3)
  35. SGLT inhibitors for type 1 diabetes: a finely balanced matter?
  36. Empagliflozin, a novel selective sodium glucose cotransporter‐2 (SGLT‐2) inhibitor: characterisation and comparison with other SGLT‐2 inhibitors
  37. Novel SGLT inhibitors (SGL5083 and SGL5085), Acting on Both Suppressing Intestinal Glucose Absorption and Increasing Urinary Glucose Excretion, Improve …
  38. SGLT-2 inhibitors: pharmacokinetics characteristics and effects on lipids
  39. SGLT inhibitors Enhance Endogenous Glucose Productions (EGP) in a Preclinical Animal Model
  40. SAT-662 Effects of SGLT inhibitors or GLP1 Analogues on Glucose Homeostasis and Body Weight in Patients with Type 1 Diabetes: A Network Meta-Analysis
  41. Correction: Synthesis of l-rhamnose derived chiral bicyclic triazoles as novel sodium-glucose transporter (SGLT) inhibitors
  42. Sodium-glucose co-transporter (SGLT) inhibitors: a novel class of oral anti-diabetic drugs
  43. Synthesis of novel l-rhamnose derived acyclic C-nucleosides with substituted 1, 2, 3-triazole core as potent sodium-glucose co-transporter (SGLT) inhibitors
  44. Cardiovascular outcomes of type 2 diabetic patients treated with SGLT-2 inhibitors versus GLP-1 receptor agonists in real-life
  45. Sodium–glucose cotransporter–2 (SGLT-2) inhibitors and the treatment of type 2 diabetes
  46. Choosing GLP-1 receptor agonists or SGLT-2 inhibitors by cardiorenal risk
  47. … -2 inhibitors and cardiovascular protection: lessons and gaps in understanding the current outcome trials and possible benefits of combining SGLT-2 inhibitors …
  48. The effect of sodium-glucose co-transporter-2 (SGLT-2) inhibitors on cardiometabolic profile; beyond the hypoglycaemic action
  49. Pharmacologic strategies to reduce cardiovascular disease in type 2 diabetes mellitus: focus on SGLT‐2 inhibitors and GLP‐1 receptor agonists
  50. The Effects of DPP-4 inhibitors, GLP-1RAs, and SGLT-2/1 inhibitors on heart failure outcomes in diabetic patients with and without heart failure history …
  51. SGLT-2 inhibitors-hope or hype?-an updated review
  52. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and …
  53. The Risk of Bladder Cancer in Type 2 Diabetes Mellitus with Combination Therapy of SGLT-2 inhibitors and Pioglitazone
  54. PDB29 A COST-UTILITY ANALYSIS OF SODIUM-GLUCOSE COTRANSPORTER (SGLT) 2 inhibitors IN ADDITION TO BASAL-BOLUS INSULIN IN THE …
  55. Systematic review and meta-analysis for prevention of cardiovascular complications using GLP-1 receptor agonists and SGLT-2 inhibitors in obese diabetic …
  56. Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes
  57. Sodium-glucose cotransporter-2 inhibitors (SGLT-2i) in the perioperative setting
  58. Sodium-glucose cotransporter-2 (SGLT-2) inhibitors for cardiovascular disease prevention
  59. Management of type 2 diabetes mellitus in older adults: eight case studies with focus SGLT-2 inhibitors and metformin
  60. Sodium-glucose cotransporter 2 (SGLT-2) inhibitors and microvascular outcomes in patients with type 2 diabetes: systematic review and meta-analysis
  61. A novel SGLT-2 score to identify HFpEF patients who may benefit from SGLT-2 inhibitors
  62. Recent Advances on SGLT 2 inhibitors: Synthetic Approaches, Therapeutic Benefits, and Adverse Events
  63. Possible sodium-glucose cotransporter-2 (SGLT-2) inhibitors for reducing effects of blood glucose and also blood pressure
  64. Outcomes of patients with type 2 diabetes treated with SGLT-2 inhibitors versus DPP-4 inhibitors. An Italian real-world study in the context of other observational …
  65. SGLT 2 inhibitors: Antidiabetic agents with promising effects beyond glucose control
  66. Update on Cardiovascular Benefits with Sodium Glucose Cotransporter-2 inhibitors (SGLT-2i). On J Cardio Res & Rep. 1 (5): 2019
  67. Cardiovascular effects of new oral glucose-lowering agents: DPP-4 and SGLT-2 inhibitors
  68. Sodium–glucose cotransporter 2 (SGLT-2) inhibitors: a new antidiabetic drug class
  69. Sodium-glucose cotransporter Type 2 (SGLT-2) inhibitors and ketogenesis: The Good and the Bad
  70. A Case Report of Euglycemic Diabetic Ketoacidosis in the Setting of Keto Diet and SGLT-2 inhibitors
  71. Sodium‐glucose co‐transporter‐2 (SGLT‐2) inhibitors and cancer: a meta‐analysis of randomized controlled trials
  72. 2232: Acute kidney injury in patients on SGLT-2 inhibitors: A propensity matched analysis
  73. Short and medium‐term efficacy of sodium glucose co‐transporter‐2 (SGLT‐2) inhibitors: A meta‐analysis of randomized clinical trials
  74. SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials
  75. 480: COMPARISON OF TREATMENT OF KETOACIDOSIS ASSOCIATED WITH SGLT-2 inhibitors AND USUAL DKA
  76. Novel oral hypoglycemic agents SGLT-2 inhibitors: cardiovascular benefits and potential mechanisms
  77. Management of type 2 diabetes mellitus with overweight: Focus on SGLT-2 inhibitors and GLP-1 receptor agonists
  78. Can sodium glucose cotransporter 2 (SGLT-2) inhibitors be beneficial in patients with acute myocardial infarction?
  79. … Association of Clinical Endocrinologists and American College of Endocrinology position statement on the association of SGLT-2 inhibitors and diabetic ketoacidosis
  80. The role of sodium glucose cotransporter-2 (SGLT-2) inhibitors in heart failure and chronic kidney disease in type 2 diabetes
  81. Comparable COVID‐19 outcomes with current use of GLP‐1 receptor agonists, DPP‐4 inhibitors or SGLT‐2 inhibitors among patients with diabetes who tested …
  82. Peripheral artery disease and amputations with Sodium-Glucose co-Transporter-2 (SGLT-2) inhibitors: A meta-analysis of randomized controlled trials
  83. Sodium-glucose cotransporter-2 inhibitors (SGLT-2i) reduce hospitalization for heart failure only and have no effect on atherosclerotic cardiovascular events …
  84. SGLT-2 inhibitors and peripheral artery disease: a statistical hoax or reality?
  85. Use of Sodium–Glucose Cotransporter 2 (SGLT-2) inhibitors Beyond Diabetes: On the Verge of a Paradigm Shift?
  86. An update on the safety and efficacy of oral antidiabetic drugs: DPP-4 inhibitors and SGLT-2 inhibitors
  87. Cardiovascular events associated with SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL 2 study
  88. SGLT-2 inhibitors: a new mechanism for glycemic control
  89. Blood pressure-lowering effect of newer antihyperglycemic agents (SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors)
  90. SGLT-2 inhibitors as second-line therapy in type 2 diabetes.
  91. In type 2 diabetes, SGLT-2 inhibitors reduce risk for major kidney outcomes
  92. SAT-685 Euglycemic Diabetic Ketoacidosis in T1d: The Era of SGLT-2 inhibitors and Keto-Diet
  93. SGLT‐2 inhibitors in heart failure: current management, unmet needs, and therapeutic prospects
  94. The kidney as a new target for antidiabetic drugs: SGLT 2 inhibitors
  95. Assessing the risk of ketoacidosis due to sodium-glucose cotransporter (SGLT)-2 inhibitors in patients with type 1 diabetes: A meta-analysis and meta …
  96. Euglycaemic diabetic ketoacidosis as a complication of SGLT-2 inhibitors: epidemiology, pathophysiology, and treatment
  97. Dynamics of epicardiac fat and heart function in type 2 diabetic patients initiated with SGLT-2 inhibitors
  98. The safety of dipeptidyl peptidase‐4 (DPP‐4) inhibitors or sodium‐glucose cotransporter 2 (SGLT‐2) inhibitors added to metformin background therapy in patients with …
  99. Combination therapy with GLP-1 analogues and SGLT-2 inhibitors in the management of diabesity: the real world experience
  100. Cardiovascular outcomes with GLP-1 receptor agonists vs. SGLT-2 inhibitors in patients with type 2 diabetes
  101. Diabetic ketoacidosis in patients with type 2 diabetes recently commenced on SGLT-2 inhibitors: an ongoing concern
  102. 194 SGLT-2 inhibitors versus GLP-1 receptor agonists and risk of mortality, chronic kidney disease and hospitalisation for heart failure in patients with type 2 diabetes
  103. Diabetes and kidney disease: the role of sodium–glucose cotransporter-2 (SGLT-2) and SGLT-2 inhibitors in modifying disease outcomes
  104. SGLT-2 inhibitors were not linked to severe or nonsevere UTIs vs DPP-4 inhibitors or GLP-1 agonists
  105. GLP-1 receptor agonists versus SGLT-2 inhibitors in obese type 2 diabetes patients
  106. Off-label prescription of SGLT-2 inhibitors to patients with type 1 diabetes: an online survey of diabetes specialists in Italy
  107. The mechanisms and clinical potential: sodium-glucose cotransporter 2 (SGLT-2) inhibitors treating diabetic kidney disease
  108. SGLT 2 inhibitors; glycemic control, weight loss and safety profile in patients with type 2 Diabetes, at Medicell Institute (MIDEM)
  109. Nephrolithiasis and sodium-glucose co-transporter-2 (SGLT-2) inhibitors: A meta-analysis of randomized controlled trials
  110. The role of SGLT-2 inhibitors in the treatment of type 2 diabetes
  111. SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials
  112. Pharmacovigilance assessment of the association between Fournier’s gangrene and other severe genital adverse events with SGLT-2 inhibitors
  113. Noninvasive monitoring of liver fat during treatment with GLP‐1 analogues and SGLT‐2 inhibitors in a real‐world setting
  114. Lower risk of heart failure and death in patients initiated on SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study.
  115. Ambulatory blood pressure reduction with SGLT-2 inhibitors: dose-response meta-analysis and comparative evaluation with low-dose hydrochlorothiazide
  116. SGLT-2 inhibitors and GLP-1 agonists: first-line therapy for diabetes with established cardiovascular disease
  117. The nephrological perspective on SGLT-2 inhibitors in type 1 diabetes
  118. A systematic review and meta-analysis of the impact of GLP-1 receptor agonists and SGLT-2 inhibitors on cardiovascular outcomes in biologically healthy …
  119. GLP-1 Agonists and SGLT-2 inhibitors in Type 2 Diabetes Patients
  120. Short-and medium-term efficacy of sodium glucose cotransporter 2 (SGLT-2) inhibitors for the treatment of type 1 diabetes: systematic review and meta-analysis
  121. MON-690 Euglycemic Diabetic Ketoacidosis Associated with SGLT-2 inhibitors-an Under-recognized Diagnosis
  122. … and biological evaluation of (2S, 3R, 4R, 5S, 6R)-5-fluoro-6-(hydroxymethyl)-2-aryltetrahydro-2H-pyran-3, 4-diols as potent and orally active SGLT dual inhibitors
  123. SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus …
  124. Does gender influence the cardiovascular benefits observed with sodium glucose co-transporter-2 (SGLT-2) inhibitors? A meta-regression analysis
  125. Sodium-glucose cotransporter 2 (SGLT-2) inhibitors for patients with Type 2 diabetes
  126. Rates of myocardial infarction and stroke in patients initiating treatment with SGLT 2‐inhibitors versus other glucose‐lowering agents in real‐world clinical practice: R …
  127. … agents in type 1 diabetes in addition to insulin therapy: metformin, alpha-glucosidase inhibitors, pioglitazone, GLP-1 agonists, DPP-IV inhibitors, and SGLT-2 inhibitors
  128. Efficacy and Safety of SGLT-2 inhibitors for Treatment of Diabetes Mellitus among Kidney Transplant Patients: A Systematic Review and Meta-Analysis
  129. SGLT-2 inhibitors: is there a role in type 1 diabetes mellitus management?
  130. Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria: a review of the clinical evidence
  131. SGLT-2 inhibitors and cardiovascular risk: an analysis of CVD-REAL
  132. How do SGLT-2 inhibitors work to prevent heart failure?
  133. SGLT-2 inhibitors as adjunctive to insulin therapy in type 1 diabetes
  134. SGLT 2 inhibitors: a systematic review of diabetic ketoacidosis and related risk factors in the primary literature
  135. Values, preferences and burden of treatment for the initiation of GLP-1 receptor agonists and SGLT-2 inhibitors in adult patients with type 2 diabetes: a …
  136. Diabetes, Antidiabetic Medications and Cancer Risk in Type 2 Diabetes: Focus on SGLT-2 inhibitors
  137. 4111 Association of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors with cardiovascular events stratified by renal function: a network meta-analysis
  138. SGLT-2 inhibitors in heart failure: implications for the kidneys
  139. SGLT-2 inhibitors and their potential in the treatment of diabetes
  140. Emerging role of SGLT-2 inhibitors for the treatment of obesity
  141. SGLT 2 inhibitors act from the extracellular surface of the cell membrane
  142. Safe and pragmatic use of sodium-glucose co-transporter 2 (SGLT 2) inhibitors: medication counseling
  143. SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis
  144. SAFETY ISSUES WITH THE USE OF SODIUM-GLUCOSE COTRANSPORTER 2 (SGLT-2) inhibitors
  145. Re: diabetic ketoacidosis in patients with type 2 diabetes on SGLT-2 inhibitors: an ongoing concern
  146. SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: a systematic review and meta-analysis of retrospective cohort studies
  147. SGLT‐2 inhibitors and the risk of lower‐limb amputation: is this a class effect?
  148. … Compounds against Type 2 Diabetes Mellitus: Proof of Concept for Sodium Dependent Glucose Transporter (SGLT) and Glycogen Phosphorylase (GP) inhibitors
  149. SGLT-2 inhibitors: potential novel strategy to prevent congestive heart failure in diabetes?
  150. Effects of SGLT-2 inhibitors on diabetic ketoacidosis: a meta-analysis of randomised controlled trials
  151. Structure–Activity Relationship Study of Acyclic Terpenes in Blood Glucose Levels: Potential α-Glucosidase and Sodium Glucose Cotransporter (SGLT-1) inhibitors
  152. Sodium-Glucose Cotransporter-2 (SGLT-2) inhibitors: Benefits in Diabetics With Cardiovascular Disease
  153. Sodium glucose cotransporter (SGLT)-2 inhibitors alleviate the renal stress responsible for sympathetic activation
  154. SGLT-2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A systematic review
  155. A look to the future in non-alcoholic fatty liver disease: Are GLP-1 analogues or SGLT-2 inhibitors the answer?
  156. Association of British Clinical Diabetologists (ABCD) position statement on the use of sodium-glucose cotransporter-2 (SGLT-2) inhibitors in type 1 diabetes
  157. P2519 Comparison of SGLT-2 inhibitors, GLP-1 agonist and DPP-4 inhibitors for mortality outcomes in participants with type 2 diabetes: a network meta-analysis of 96 …
  158. Application of new glucose lowering drugs: DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors
  159. Effects of GLP-1 Receptor Agonists and SGLT-2 inhibitors in Heart Transplant Patients with Type 2 Diabetes: a Case Series
  160. Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials
  161. The beneficial hemodynamic actions of SGLT-2 inhibitors beyond the management of hyperglycemia
  162. Sodium–glucose co-transporter-2 (SGLT-2) inhibitors in patients with type 2 diabetes mellitus: the road ahead
  163. Combination of SGLT-2 inhibitors and GLP-1 receptor agonists: potential benefits in surrogate and hard endpoints
  164. Class effect for SGLT-2 inhibitors: a tale of 9 drugs
  165. Effects of GLP-1 receptor agonists and SGLT-2 inhibitors in heart transplant patients with type 2 diabetes: Initial report from a cardiometabolic center of excellence
  166. Do the SGLT-2 inhibitors offer more than hypoglycemic activity?
  167. Adverse effects and safety of SGLT-2 inhibitors
  168. New diabetes therapies and diabetic kidney disease progression: the role of SGLT-2 inhibitors
  169. 66 Acute coronary syndrome in type 2 diabetes treated using SGLT-2 inhibitors, GLP-1 agonists and DPP-4 inhibitors: a comparative network meta-analysis of …
  170. Long-term effectiveness and safety of SGLT-2 inhibitors in an Italian cohort of patients with type 2 diabetes mellitus
  171. Differential indication for SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with established atherosclerotic heart disease or at risk for congestive heart …
  172. Sodium Glucose Co-Transporter 2 (SGLT-2) inhibitors: A Review
  173. Comparable COVID-19 outcomes with current use of GLP-1 receptor agonists, DPP-4 inhibitors or SGLT-2 inhibitors among patients with diabetes who tested positive …
  174. 1233-P: Systematic Literature Review (SLR) and Network Meta-analysis (NMA) of SGLT-1/2 inhibitors vs. Metformin (MET) as Add-On to Insulin in T1DM
  175. 301P Sodium-glucose cotransporter-2 (SGLT-2) inhibitors for alpelisib (ALP)-induced hyperglycemia: A report of 6 cases from SOLAR-1
  176. Comparison in Methods Between National Institute for Health And Care Excellence (Nice) Submissions For Sodium-Glucose Co-Transporter 2 inhibitors (SGLT-2i …
  177. The different hypoglycemic effects between East Asian and non-Asian type 2 diabetes patients when treated with SGLT-2 inhibitors as an add-on treatment for …
  178. Comparative efficacy of once-weekly semaglutide and SGLT-2 inhibitors in type 2 diabetic patients inadequately controlled with metformin monotherapy: a systematic …
  179. SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline
  180. SGLT-2 inhibitors for COVID-19—A miracle waiting to happen or just another beat around the bush?
  181. Early initiation of sodium‐glucose linked transporter inhibitors (SGLT‐2i) and associated metabolic and electrolyte outcomes in diabetic kidney transplant recipients
  182. SGLT-2 inhibitors and nephroprotection: current evidence and future perspectives
  183. Heart failure hospitalization with SGLT-2 inhibitors: a systematic review and meta-analysis of randomized controlled and observational studies
  184. Comparing SGLT-2 inhibitors to DPP-4 inhibitors as an add-on therapy to metformin in patients with type 2 diabetes: A systematic review and meta-analysis
  185. An updated perspective and pooled analysis of cardiovascular outcome trials of GLP-1 receptor agonists and SGLT-2 inhibitors
  186. SGLT-2 inhibitors may be targeting higher risk patients with diabetes possibly justifying higher cost: Single center repeated cross-sectional analysis
  187. Association Between Sodium-Glucose Cotransporter-2 (SGLT-2) inhibitors and Lower Extremity Amputation: A Retrospective Cohort Study
  188. Stroke paradox with SGLT-2 inhibitors: a play of chance or a viscosity-mediated reality?
  189. SGLT-2 inhibitors in heart failure and type-2 diabetes: hitting two birds with one stone?
  190. SGLT-2 inhibitors: a novel mechanism in targeting glycemic control in type 2 diabetes mellitus
  191. Are SGLT-2 inhibitors the future of heart failure treatment? The EMPEROR-Preserved and EMPEROR-Reduced trials
  192. The effect of SGLT-2 inhibitors on blood pressure: a pleiotropic action favoring cardio-and nephroprotection
  193. SGLT-2 inhibitors as promising therapeutics for non-alcoholic fatty liver disease: pathophysiology, clinical outcomes, and future directions
  194. Use of SGLT-2 inhibitors in patients with type 2 diabetes mellitus and abdominal obesity: an Asian perspective and expert recommendations
  195. Elements for Success in Managing Type 2 Diabetes With SGLT-2 inhibitors: Role of the Kidney in Glucose Homeostasis: Implications for SGLT-2 Inhibition in the …
  196. The role of SGLT-2 inhibitors as part of optimal medical therapy in improving cardiovascular outcomes in patients with diabetes and coronary artery disease
  197. Best practices for safe use of SGLT-2 inhibitors developed from an expert panel Delphi consensus process
  198. SGLT-2 inhibitors: diabetes treatment by glycosuria; literature review on the effect of dapagliflozin
  199. Sodium glucose cotransporter (SGLT)‐2 inhibitors: Do we need them for glucose‐lowering, for cardiorenal protection or both?
  200. SGLT-2 inhibitors and cardiovascular risk in diabetes mellitus: a comprehensive and critical review of the literature
  201. Liraglutide versus SGLT-2 inhibitors in people with type 2 diabetes: a network meta-analysis
  202. SGLT-2 receptor inhibitors: An opportunity to revise our therapeutic strategy for type 2 diabetes?
  203. SGLT-2 inhibitors: their pleiotropic properties
  204. Diabetes Consultations™: Beyond Insulin: The Role of SGLT-2 inhibitors in Care of Patients with T1DM
  205. In patients with uncontrolled type 2 diabetes, are GLP-1 agonists more effective than SGLT-2 inhibitors in lowering HbA1c?
  206. Incretin based therapies and SGLT-2 inhibitors in kidney transplant recipients with diabetes: A systematic review and meta-analysis
  207. The effect of SGLT-2 inhibitors on albuminuria and proteinuria in diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials
  208. Challenges in simultaneous extraction and chromatographic separation of metformin and three SGLT-2 inhibitors in human plasma using LC–MS/MS
  209. CHARACTERISTICS OF PATIENTS INITIATING SODIUM GLUCOSE COTRANSPORTER-2 inhibitors (SGLT-2I) COMPARED TO PATIENTS INITIATING OTHER …
  210. SGLT-2 inhibitors: A step forward in the treatment of heart failure with reduced ejection fraction
  211. Gender difference in cardiovascular outcomes with SGLT-2 inhibitors and GLP-1 receptor agonist in type 2 diabetes: a systematic review and meta-analysis of cardio …
  212. SGLT-2 inhibitors reduce glucose absorption from peritoneal dialysis solution by suppressing the activity of SGLT-2
  213. SGLT-2 inhibitors associated euglycemic and hyperglycemic DKA in a multicentric cohort
  214. SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system
  215. SGLT-2 inhibitors and DPP-4 inhibitors as second-line drugs in patients with type 2 diabetes: a meta-analysis of randomized clinical trials
  216. Renal benefits of SGLT 2 inhibitors and GLP-1 receptor agonists: evidence supporting a paradigm shift in the medical management of type 2 diabetes
  217. Cardiovascular outcomes with SGLT-2 inhibitors and GLP-1 receptor agonist in Asians with type 2 diabetes: a systematic review and meta-analysis of cardiovascular …
  218. Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney …
  219. Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic …
  220. Spotlight on Canagliflozin 300: review of its efficacy and an indirect comparison to other SGLT-2 inhibitors and long-acting GLP-1 receptor agonists
  221. Sodium-Glucose Cotransporter 2 (SGLT-2) inhibitors: Delving Into the Potential Benefits of Cardiorenal Protection Beyond the Treatment of Type-2 Diabetes …
  222. Let’s Be More Sensitive—How SGLT-2 inhibitors and GLP-1 Receptor Agonists Affect β-Cell Function in Type 2 Diabetes: Comment on “Improved Beta Cell Glucose …
  223. Letter by Tampaki et al Regarding Article,“Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 inhibitors”
  224. Cardiovascular Outcomes with SGLT-2 inhibitors in patients with heart failure with or without type 2 diabetes: A systematic review and meta-analysis of randomized …
  225. Does background metformin therapy influence the cardiovascular outcomes with SGLT-2 inhibitors in type 2 diabetes?
  226. Toe amputations with SGLT-2 inhibitors: data from randomized clinical trials
  227. SGLT-2 inhibitors in diabetes: a focus on renoprotection
  228. Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational …
  229. The placebo response of injectable GLP‐1 receptor agonists vs. oral DPP‐4 inhibitors and SGLT‐2 inhibitors: a systematic review and meta‐analysis
  230. Mechanisms for Cardiorenal Protection of SGLT-2 inhibitors
  231. Use of SGLT-2 inhibitors in the treatment of type 2 diabetes mellitus
  232. SGLT-2 inhibitors in development for type 2 diabetes treatment
  233. SGLT-2 inhibitors in type 1 diabetes mellitus: a comprehensive review of the literature
  234. Cardiovascular effects of SGLT‐2 inhibitors: What we have learned from cardiovascular outcome trials and what we still need to understand
  235. Response to letter:’Acute heart failure, type 2 diabetes and loop diuretic use: any adjunct role for SGLT-2 inhibitors?’
  236. Efficacy in metabolic control and weight loss of combined treatment with GLP-1 receptor analogues and SGLT-2 inhibitors
  237. SGLT-2 inhibitors in heart failure: A new therapeutic avenue
  238. Hyperglycemic, high anion-gap metabolic acidosis in patients receiving SGLT-2 inhibitors for diabetes management
  239. SGLT-2 inhibitors to treat hyponatremia associated with SIADH: a novel indication?
  240. Do SGLT‐2 inhibitors exhibit similar cardiovascular benefit in patients with heart failure with reduced or preserved ejection fraction?
  241. Differentiating Among the SGLT-2 inhibitors: Considering Cardiovascular and Other Safety Outcomes
  242. … -transporter 2 inhibitors and serum uric acid: Re: Mende CW. Diabetes and kidney disease: the role of sodium-glucose cotransporter-2 (SGLT-2) and SGLT-2 inhibitors …
  243. Newer classes of antidiabetes drugs: ophthalmological considerations for GLP-1R agonists, DPP-4 inhibitors, and SGLT-2 inhibitors
  244. Sodium-Glucose Co-Transporter-2 (SGLT-2) inhibitors And The Risk of Fractures of The Upper or Lower Limb In Patients With Type 2 Diabetes: A Nested-Case …
  245. Protective effects of SGLT-2 inhibitors across the cardiorenal continuum: two faces of the same coin
  246. Antidiabetic SGLT-2 inhibitors prevent progression of chronic kidney disease
  247. The use of SGLT-2 inhibitors in type 2 diabetes and heart failure
  248. Hospitalization for Heart Failure and Death in New Users of SGLT-2 inhibitors in Patients With and Without Cardiovascular Disease—CVD Real Study
  249. A Role for SGLT-2 inhibitors in Treating Non-diabetic Chronic Kidney Disease
  250. Effect of background insulin therapy on cardiovascular outcomes with SGLT-2 inhibitors in type 2 diabetes: A meta-analysis of cardiovascular outcome trials
  251. The role of self-monitoring of blood glucose in patients treated with SGLT-2 inhibitors: a European expert recommendation
  252. Sodium‐glucose cotransporter (SGLT) 2 inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the …
  253. Comparative pharmacokinetics of three SGLT-2 inhibitors sergliflozin, remogliflozin and ertugliflozin: an overview
  254. Limitations of natriuretic peptide levels in establishing SGLT-2 inhibitors for heart failure care
  255. Prevention of cardiac allograft vasculopathy–A new possible indication for SGLT-2 inhibitors?
  256. SGLT-2 inhibitors as cardioprotective agents in COVID-19
  257. Challenges in Implementing Evidence Based Cross-Disciplinary Therapies: Are Cardiovascular Specialists Ready to Claim SGLT-2 inhibitors and GLP-1 Analogs?
  258. SGLT-2 inhibitors Use in Renal Transplant Patients with Diabetes: A Brief Review of the Current Literature.
  259. Lower Risk of Cardiovascular Events and Death Associated with Initiation of SGLT-2 inhibitors versus Other Glucose Lowering Drugs-Real World Data Across …
  260. SGLT-2 inhibitors Beneficial Effects on Ventricular Repolarization May Be Protective against Atrial Fibrillation Occurrence
  261. SGLT-2 inhibitors and regenerative cell exhaustion
  262. Clinical Spectrum and Mechanism of Acute Kidney Injury in Patients with Diabetes Mellitus on SGLT-2 inhibitors.
  263. SGLT-2 inhibitors in Heart Failure: Guide for Prescribing and Future Perspectives
  264. The effect of SGLT‐2 inhibitors on mortality and heart failure in randomized trials versus observational studies
  265. … Effects of Central Nervous System Between Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) and Sodium Glucose Co-Transporter-2 inhibitors (SGLT …
  266. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) in patients with type 2 …
  267. SGLT‐2 inhibitors and the risk of hospitalization for community‐acquired pneumonia: A population‐based cohort study
  268. SGLT-2 inhibitors: Ideal Remedy for Cardioprotection in Diabetes Mellitus.
  269. Comparative efficacy of once-weekly semaglutide versus SGLT-2 inhibitors in patients inadequately controlled with one to two oral antidiabetic drugs: a …
  270. Combination therapy with SGLT-2 inhibitors and GLP-1 receptor agonists as complementary agents that address multi-organ defects in type 2 diabetes
  271. SGLT‐2 inhibitors and ketoacidosis: a disproportionality analysis in the World Health Organization’s adverse drug reactions database
  272. Translating the statistical benefits of SGLT-2 inhibitors on cardio-renal outcomes into clinical practice
  273. Perioperative euglycemic diabetic ketoacidosis following use of SGLT-2 inhibitors after cardiac surgery
  274. Effects of cardiovascular function of SGLT-2 inhibitos versus DPP-4 inhibitors in type 2 diabetes with coronary artery disease
  275. Can SGLT-2 inhibitors resolve the heart failure burden of diabetes mellitus-Is it empaglifozin or the class?
  276. SGLT-2 inhibitors in diabetic kidney disease: what lies behind their renoprotective properties?
  277. Efficacy of SGLT-2 inhibitors in older adults with diabetes: systematic review with meta-analysis of cardiovascular outcome trials
  278. Exploring the heterogeneity of the effects of SGLT-2 inhibitors in cardiovascular outcome trials
  279. … THE DIFFERENCES EFFECTS OF GLUCAGON LIKE PEPTIDE-1 (GLP-1) ANALOGUES AND SODIUM-COTRANSPORTER 2 (SGLT-2) inhibitors ON TYPE 2 …
  280. Dapagliflozin and renal function. Re: Diabetes and kidney disease: the role of sodium–glucose cotransporter-2 (SGLT-2) and SGLT-2 inhibitors in modifying disease …
  281. Effect of SGLT-2 inhibitors on non-alcoholic fatty liver disease among patients with type 2 diabetes mellitus: Systematic review with meta-analysis and trial …
  282. A study of the effects of SGLT-2 inhibitors on diabetic cardiomyopathy through miR-30d/KLF9/VEGFA pathway
  283. SGLT-2 inhibitors in Heart Failure: Volume or Value?
  284. SGLT-2 inhibitors users profile recruited through a pharmacy-based intensive monitoring study: analysis of the pharmacotherapeutic profile, drug-drug interactions …
  285. The role of SGLT-2 inhibitors in managing type 2 diabetes.
  286. Use of SGLT-2 inhibitors in Patients With Type 1 Diabetes Mellitus
  287. In Reply to ‘Do SGLT-2 inhibitors Act Only Through a Functional Tubuloglomerular Feedback Induced by the Increased Outflow of Sodium?’
  288. Postoperative euglycemic diabetic ketoacidosis and encephalopathy related to SGLT-2 inhibitors: a case report and discussion of diabetes treatment and “sweet pee …
  289. Trends in SGLT-2 inhibitors Usage in Heart Failure Patients With Type 2 Diabetes Mellitus, in a South-East Queensland Hospital
  290. SGLT-2 inhibitors for people with type 2 diabetes–Authors’ reply
  291. … and patient-centred outcome measures in randomized controlled trials conducted for diabetes pharmacotherapy: SGLT-2 receptor inhibitors as an example
  292. Implementing the treatment of heart failure with SGLT-2 inhibitors and sacubitril–valsartan: does money matter?
  293. SGLT-2 inhibitors: are they a promising treatment option in T2DM patients with NAFLD?
  294. Do SGLT-2 inhibitors reduce albuminuria in people with diabetes?
  295. Renal Effects of SGLT‐2 inhibitors and Other Anti‐diabetic Drugs: Clinical Relevance and Potential Risks
  296. Ketogenic Diets, Ketoacidosis and SGLT-2 inhibitors-Part 2..
  297. Chronic kidney disease and diabetes status do not affect efficacy of SGLT-2 inhibitors in patients with heart failure with reduced ejection fraction
  298. MON-602 The Efficacy and Safety of Sodium-Glucose Transport Protein 2 (SGLT-2) inhibitors for Weight Loss Among Individuals Without Diabetes: A Systematic …
  299. … Risk of Death and Cardiovascular Events in Unselected Type 2 Diabetes Patients Initiated on GLP-1 Receptor Agonists and SGLT-2 inhibitors in Two Large …
  300. SGLT-2 inhibitors—a Culprit of Diabetic Ketoacidosis Postbariatric Surgery
  301. Best practices for safe use of SGLT-2 inhibitors developed from an expert panel Delphi consensus process
  302. … Reporting and Data System Category 3 (Equivocal) Lesions Identified Infection and Inflammation of the Genitourinary Tract Re: SGLT-2 inhibitors and the Risk of …
  303. SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus …
  304. Falls and SGLT-2 inhibitors in geriatric patients—A case report
  305. The Effect of SGLT-2 inhibitors and GLP-1 Agonists on Cardiovascular Disease in Patients with Type 2 Diabetes
  306. Systematic review and meta-analysis of the effect of SGLT-2 inhibitors on microvascular outcomes in patients with type 2 diabetes: a review protocol
  307. A Comprehensive Review on Analytical Method Development and Validation for SGLT-2 inhibitors by HPLC in Its API and Dosage Form
  308. Cardiometabolic Risk Reduction: A Review of Clinical Guidelines and the Role of SGLT-2 inhibitors
  309. Euglycemic Diabetic Ketoacidosis, SGLT-2 inhibitors and COVID-19; The Murphy Law of COVID-19
  310. Development of Efficient Routes to Access C-Glycosides as SGLT-2 inhibitors for the Treatment of Type 2 Diabetes
  311. Current Utilization Trends of SGLT-2 inhibitors in Type 2 Diabetics With Heart Failure
  312. SGLT-2 inhibitors for people with type 2 diabetes
  313. The placebo response of injectable GLP‐1 receptor agonists vs. oral DPP‐4 inhibitors and SGLT‐2 inhibitors: a systematic review and meta‐analysis
  314. SGLT-2 inhibitors: A new era in managing diabetic kidney disease starts now
  315. SGLT-2 inhibitors: a novelty in the treatment of type 2 diabetes
  316. P2482 Sex-based differences in cardioprotective role of SGLT-2 inhibitors in patients with type 2 diabetes mellitus
  317. Correlations Between SGLT-2 inhibitors and Acute Renal Failure by Signal Detection Using FAERS: Stratified Analysis for Reporting Country and Concomitant Drugs
  318. Expect the Unexpected: SGLT-2 inhibitors in the Treatment of Type 2 Diabetes and/or Heart Failure
  319. Analysis of Adverse Drug Reactions Induced by SGLT-2 inhibitors
  320. SGLT-2 inhibitors in heart failure: An updated systematic review and meta-analysis of 13 randomized clinical trials including 14618 patients with heart failure.
  321. SGLT-2 inhibitors DEMONSTRATE CONSISTENT REDUCTION IN CARDIOVASCULAR MORTALITY AND HEART FAILURE HOSPITALIZATIONS AN UP-TO …
  322. Overview of the efficacy and safety of SGLT-2 inhibitors in type 2 diabetes mellitus
  323. The effects of sodium glucose co-transporter (SGLT) 2 inhibitors on hematocrit levels: a systematic review and meta-analysis of randomized controlled trials.
  324. Glycosuria with SGLT-2 inhibitors–a new treatment approach for type 2 diabetes mellitus
  325. SGLT-2 inhibitors and circulating progenitor cells in diabetes
  326. Improving Glucose Control in Type II Diabetes with SGLT-2 inhibitors and GLP-1 Agonists
  327. Do SGLT-2 inhibitors improve cardiovascular outcomes in patients with type 2 diabetes?
  328. SGLT-2 inhibitors for people with type 2 diabetes
  329. Kidney Outcomes With SGLT-2 inhibitors
  330. SGLT-2 inhibitors and nephroprotection: a systematic review and meta-analysis
  331. SGLT-2 inhibitors-are they to stay?
  332. SGLT-2 inhibitors as adjunct therapy in type 1 diabetes: reason for hope and caution
  333. The method of reporting hypoglycemia in randomized control trials (RCTs): a systematic review on RCTs conducted for SGLT-2 inhibitors
  334. SGLT-2 inhibitors: The glucosuric antidiabetics
  335. SYSTEMATIC REVIEW OF COST-EFFECTIVENESS OF SGLT-2 inhibitors IN TYPE 2 DIABETES MELLITUS
  336. SGLT-2-inhibitors in Heart Failure
  337. SGLT 2 inhibitors: a new therapeutic target and its role in current clinical practice
  338. Renoprotective effect of SGLT-2 inhibitors vs​ ACE inhibitors in type 2 diabetes (presentation)
  339. Renoprotective effect of SGLT-2 inhibitors vs​ ACE inhibitors in type 2 diabetes
  340. FO042 EFFECT OF SGLT-2 inhibitors ON AMBULATORY BLOOD PRESSURE: DOSE-RESPONSE META-ANALYSIS AND COMPARATIVE EVALUATION WITH …
  341. Need of the hour: pharmacovigilance study of SGLT-2 inhibitors
  342. PDB13-SYSTEMATIC LITERATURE REVIEW AND NETWORK META-ANALYSIS OF SGLT-2 inhibitors AND METFORMIN AS ADD-ON TO INSULIN FOR THE …
  343. Diabetes Management and Cardiovascular Risk: Are SGLT-2 inhibitors the Safest?
  344. The effect of SGLT-2 inhibitors on albuminuria and proteinuria in Diabetes Mellitus: a systematic review and meta–analysis of randomized controlled trials
  345. Falls and SGLT-2 inhibitors in geriatric patients—A
  346. SGLT 2 inhibitors improve cardiorenal outcomes in DM2–get rid of the sugar
  347. A meta-analysis of the effect of sodium glucose cotransporter-2 inhibitors (SGLT-2is) on metabolic parameters in patients with polycystic ovary syndrome (PCOS …
  348. MON-LB029 The Influence of SGLT-2 inhibitors and Other Glucose-Lowering Therapies on All-Cause Mortality Risk and Cardiovascular Outcomes in Older Patients …
  349. KETOACIDOSIS GENERATED BY TREATMENT WITH SGLT-2 inhibitors–A CASE REPORT
  350. Victoza®(liraglutide) provides greater glycaemic control than SGLT-2 inhibitors
  351. A Meta-Analysis of the Effects of SGLT-2 inhibitors on Serum Electrolytes
  352. Effect of SGLT-2 inhibitors on cardiovascular outcomes in heart failure patients: A meta-analysis of randomized controlled trials
  353. REAL WORLD SAFETY AND EFFICACY OF SGLT-2 inhibitors IN ELDERLY TYPE 2 DIABETIC PATIENTS
  354. The Influence of SGLT-2 inhibitors and Other Glucose-Lowering Therapies on Mortality Risk in Elderly Patients with Type 2 Diabetes
  355. Comparison of the effects of SGLT 2 inhibitors and sulfonylurea on electrocardiographic parameters
  356. Prescribing patterns of SGLT-2 inhibitors and GLP-1 agonist in patients with both DM and ASCVD
  357. SGLT-2 inhibitors
  358. TREATMENT WITH SGLT-2 inhibitors IN PATIENTS WITH DIABETES MELLITUS AND ESSENTIAL HYPERTENSION–DYNAMIC OF BLOOD PRESSURE VISIT-TO …
  359. Use of SGLT-2 inhibitors in Patients with Chronic Kidney Disease.
  360. Effect of SGLT-2 inhibitors on Cardiovascular Outcomes Among Patients With Heart Failure and Type 2 Diabetes Mellitus: A Systemic Review and Meta …
  361. Effects of SGLT-2 inhibitors and Visceral Fat on Glucose Metabolism
  362. SGLT-2 inhibitors and amputation: A real or an overestimated risk?
  363. SGLT-2 inhibitors: a new therapy for diabetes
  364. SGLT-2 inhibitors as adjunctive therapy in type 1 diabetes: Short experience from a center
  365. SGLT-2 inhibitors: An Evidence-Based Perspective
  366. Advances in cardiovascular safety of SGLT-2 inhibitors and GLP-1 receptor agonists
  367. A Multivariate Safety and Efficacy Analysis of Prescribing Information for Next Generation SGLT-2 inhibitors in Type 2 Diabetes Treatment
  368. SGLT-2 inhibitors in type 2 diabetes-protecting the kidney (and heart) beyond glucose control
  369. WHAT PHYSICIANS NEED TO KNOW ABOUT SGLT-2 inhibitors
  370. Cerebrovascular Complications of Diabetes: SGLT-2 inhibitors as a Promising Future Therapeutics.
  371. SGLT-2 inhibitors–aT The LimiTS
  372. Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives
  373. SGLT inhibitor adjunct therapy in type 1 diabetes
  374. Contribution of hyperglycemia on diabetic complications in obese type 2 diabetic SDT fatty rats: effects of SGLT inhibitor phlorizin
  375. Sodium-glucose co-transporter (SGLT) inhibitor restores lost axonal varicosities of the myenteric plexus in a mouse model of high-fat diet-induced obesity
  376. Optimizing SGLT inhibitor treatment for diabetes with chronic kidney diseases
  377. Effects of the SGLT‐2 inhibitor dapagliflozin on glomerular and tubular injury markers
  378. Pharmacological investigations on efficacy of Phlorizin a sodium-glucose co-transporter (SGLT) inhibitor in mouse model of intracerebroventricular streptozotocin …
  379. Modeling effects of SGLT‐2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes
  380. Restoration of the Attenuated Neuroprotective Effect of Ischemic Postconditioning in Diabetic Mice by SGLT inhibitor Phlorizin
  381. The SGLT-2 inhibitor dapagliflozin has a therapeutic effect on atherosclerosis in diabetic ApoE−/− mice
  382. 24-hour blood pressure-lowering effect of an SGLT-2 inhibitor in patients with diabetes and uncontrolled nocturnal hypertension: results from the randomized …
  383. DPP-4 inhibitor plus SGLT-2 inhibitor as combination therapy for type 2 diabetes: from rationale to clinical aspects
  384. Interaction of the sodium/glucose cotransporter (SGLT) 2 inhibitor canagliflozin with SGLT1 and SGLT2: inhibition kinetics, sidedness of action, and transporter …
  385. Glycemic effects of SGLT-2 inhibitor Canagliflozin in type 1 diabetes patients using the dexcom G4 platinum CGM
  386. Consensus Report on Diabetic Ketoacidosis and Adjunctive SGLT inhibitor Therapy in Type 1 Diabetes
  387. The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with …
  388. Effects of the SGLT-2 inhibitor empagliflozin on renal tissue oxygenation in non-diabetic subjects: a randomized, double-blind, placebo-controlled study …
  389. Novel SGLT inhibitor (SGL5094) Improves Postprandial Hyperglycemia Through the Suppression of SGLT1-Mediated Glucose Transport Across the Small Intestine.
  390. Anti-inflammatory effect for atherosclerosis progression by sodium-glucose cotransporter 2 (SGLT-2) inhibitor in a normoglycemic rabbit model
  391. … , tolerability, pharmacokinetics and pharmacodynamics of single doses of empagliflozin, a sodium glucose cotransporter-2 (SGLT-2) inhibitor, in healthy Japanese …
  392. Ertugliflozin: a sodium-glucose cotransporter-2 (SGLT-2) inhibitor for glycemic control in type 2 diabetes
  393. Efficient Synthesis of Empagliflozin, an inhibitor of SGLT-2, Utilizing an AlCl3-Promoted Silane Reduction of a β-Glycopyranoside
  394. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial
  395. Empagliflozin, a novel potent and selective SGLT‐2 inhibitor, improves glycaemic control alone and in combination with insulin in streptozotocin‐induced diabetic rats …
  396. Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT-2) inhibitor, coadministered with sitagliptin in healthy volunteers
  397. Empagliflozin, SGLT 2 inhibitor, attenuates renal fibrosis in rats exposed to unilateral ureteric obstruction: potential role of Klotho expression
  398. Renoprotective effects of combined SGLT 2 and ACE inhibitor therapy in diabetic D ahl S rats
  399. SGLT-2 inhibitor therapy added to GLP-1 agonist therapy in the management of T2DM
  400. Effects of the sodium‐glucose cotransporter 2 (SGLT 2) inhibitor velagliflozin, a new drug with therapeutic potential to treat diabetes in cats
  401. Long‐term treatment with empagliflozin, a novel, potent and selective SGLT‐2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic …
  402. Euglycaemic diabetic ketoacidosis in a 43-year-old woman with type 2 diabetes mellitus on SGLT-2 inhibitor (empagliflozin)
  403. Efficacy and safety of adding sotagliflozin, a dual sodium‐glucose co‐transporter (SGLT) 1 and SGLT2 inhibitor, to optimized insulin therapy in adults with type 1 …
  404. … and attenuates the development of diabetic cardiomyopathy in mice with type 2 diabetes. Further augmentation of the effects with saxagliptin, a DPP4 inhibitor
  405. Off-target effects of sodium-glucose cotransporter 2 (SGLT-2) inhibitor in cardiovascular disease
  406. A validated LC‐MS/MS method for the determination of canagliflozin, a sodium–glucose co‐transporter 2 (SGLT‐2) inhibitor, in a lower volume of rat plasma …
  407. The effects of intermittent use of the SGLT-2 inhibitor, dapagliflozin, in overweight patients with type 2 diabetes in Japan: a randomized, crossover, controlled clinical …
  408. A single dose of dapagliflozin, an SGLT-2 inhibitor, induces higher glycosuria in GCK-and HNF1A-MODY than in type 2 diabetes mellitus
  409. Efficacy and safety of dual SGLT 1/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials
  410. The sodium glucose cotransporter-2 (SGLT-2) inhibitor empagliflozin lowers blood pressure independent of weight or HbA1c changes
  411. Assessing the cost-effectiveness of a once-weekly GLP-1 analogue versus an SGLT-2 inhibitor in the Spanish setting: once-weekly semaglutide versus empagliflozin
  412. Canagliflozin, an SGLT-2 inhibitor, ameliorates acetic acid-induced colitis in rats through targeting glucose metabolism and inhibiting NOX2
  413. Very low carbohydrate diet and SGLT-2-inhibitor: double jeopardy in relation to ketoacidosis
  414. A quantitative LC–MS/MS method for determining ipragliflozin, a sodium-glucose co-transporter 2 (SGLT-2) inhibitor, and its application to a pharmacokinetic study in …
  415. Effect of a selective SGLT 2 inhibitor, luseogliflozin, on circadian rhythm of sympathetic nervous function and locomotor activities in metabolic syndrome rats
  416. Back off to better blow up: acute GFR decrease at SGLT-2 inhibitor initiation
  417. SGLT2 inhibitor-induced euglycaemic diabetic ketoacidosis may be due to abrupt, severe and transient impaired glucose sensing in susceptible individuals …
  418. Factors associated with A1C reduction with GLP-1 agonist or SGLT-2 inhibitor use
  419. Liraglutide and dulaglutide therapy in addition to SGLT-2 inhibitor and metformin treatment in Indian type 2 diabetics: a real world retrospective observational …
  420. SGLT-2 inhibitor intervention in diabetes mellitus patients can reduce the incidence of renal injury and adverse events
  421. SGLT‐2 inhibitor Renal Outcome Modification in Type‐2 Diabetes: Evidence from Studies in Patients with High or Low Renal Risk
  422. Profile of Ipragliflozin, an Oral SGLT-2 inhibitor for the Treatment of Type 2 Diabetes: The Evidence to Date
  423. Fournier’s gangrene under SGLT-2 inhibitor therapy: A literature review and case report
  424. Synthesis of SGLT-2 inhibitor Empagliflozin
  425. Invited review. Series: Implications of the recent CVOTs in type 2 diabetes: Which patients for GLP-1RA or SGLT-2 inhibitor?
  426. 442: Diagnosis and Management of SGLT-2 inhibitor-Induced Euglycemic DKA After Cardiac Surgery
  427. Systematic review of metformin monotherapy and dual therapy with sodium glucose co-transporter 2 inhibitor (SGLT-2) in treatment of type 2 diabetes mellitus
  428. A practical stereoselective synthesis and novel cocrystallizations of an amphiphatic SGLT-2 inhibitor
  429. The SGLT-2 inhibitor empagliflozin preserves beta cell mass and restores glucose homeostasis in the male diabetic ZDF rat
  430. US Prevalence of Individuals With Diabetes and Chronic Kidney Disease Indicated for SGLT-2 inhibitor Therapy
  431. Ertugliflozin: a new option in the SGLT-2 inhibitor market for the treatment of type 2 diabetes mellitus
  432. Improvement in glycaemic parameters using SGLT-2 inhibitor and GLP-1 agonist in combination in an adolescent with diabetes mellitus and Prader-Willi syndrome: a …
  433. Euglycaemic diabetic ketoacidosis in a 43-year-old woman with type 2 diabetes mellitus on SGLT-2 inhibitor (empagliflozin)
  434. Excess weight loss in a patient with type 2 diabetes mellitus treated with an SGLT-2 inhibitor
  435. Abstract# 1040609: SGLT-2 inhibitor Prescribing Patterns at Tertiary Care Diabetes Center for Individuals with Diabetes and Heart Failure
  436. … for cost-savings in the elderly Ontarian population with type 2 diabetes due to reduction in mild hypoglycemia events for SGLT-2 inhibitor versus sulfonylurea (SU) …
  437. Tubuloglomerular feedback in renal glucosuria: mimicking long-term SGLT-2 inhibitor therapy
  438. … -1 RECEPTOR AGONIST AND SGLT-2 inhibitor COMBINATION ON BLOOD PRESSURE LEVELS COMPARED TO SGLT-2 inhibitor ALONE: A SYSTEMATIC …
  439. The SGLT-2 inhibitor dapagliflozin reduces cell death and apoptosis in cardiomyocytes exposed to trastuzumab and doxorubicin through NLRP3-mediated pathways.
  440. Euglycemic diabetic ketoacidosis precipitated by SGLT-2 inhibitor use, pericarditis, and fasting: a case report
  441. Euglycemic diabetic ketoacidosis caused by a sodium-glucose co-transporter (SGLT) 2 inhibitor after coronary artery bypass grafting
  442. P722 Glycemic control with canagliflozin, a SGLT-2 inhibitor, attenuates atherosclerosis and endothelial dysfunction in diabetic apolipoprotein e-deficient mice
  443. P2295 SGLT 2 inhibitor suppresses atrial fibrillation in the canine model of atrial fibrillation
  444. … stage rapidly progressive diabetic nephropathy effectively treated with combination therapy including RAS blocker, GLP-1 receptor agonist and SGLT-2 inhibitor
  445. Novel SGLT 2 inhibitor: first‐in‐man studies of antisense compound is associated with unexpected renal effects
  446. Hypomagnesemia-Induced Hypocalcemia Successfully Treated With Sodium-Glucose Cotransport inhibitor (SGLT-2i), a Case Report
  447. Sodium Glucose Cotransporter-2 (SGLT-2) inhibitor Related Diabetic Ketoacidosis
  448. About the choice between a DPP-4 inhibitor and a SGLT 2 inhibitor tor treating type 2 diabetes
  449. Sodium-Glucose Cotransporter 2 (SGLT-2) inhibitor drugs: Assessment of safety in Fasting Diabetics
  450. Abstract# 998903: Euglycemic Relapsing Diabetic Ketaocidosis Due to SGLT-2 inhibitor Use: A Metabolic Challenge in Need of Substrate
  451. Abstract# 1000873: Euglycemic Relapsing Diabetic Ketaocidosis Due to SGLT-2 inhibitor Use: A Metabolic Challenge in Need of Substrate
  452. A promising combination for future treatment of type 2 diabetes: Coadministration of empagliflozin (SGLT-2 inhibitor) with linagliptin (DPP-4 inhibitor)
  453. Evaluation of glycemic control by metformin+ glitazone+ DPP-4 inhibitor+ SGLT-2 inhibitor combination in patients with type 2 diabetes quitting basal/bolus …
  454. US Prevalence Estimates of Individuals With Diabetes and Chronic Kidney Disease Indicated for SGLT-2 inhibitor Initiation
  455. Remogliflozin: the new low cost SGLT-2 inhibitor for type 2 diabetes mellitus
  456. Renal outcomes and all-cause death associated with SGLT-2 inhibitor versus other glucose-lowering drugs (CVD-REAL 3 Korea).
  457. Individualizing treatment with SGLT-2 inhibitor therapy in type 2 diabetes mellitus
  458. Abstract P233: Sodium Glucose Transporter Type-2 (SGLT-2) inhibitor, Empagliflozin, Improves Cardiovascular Outcomes in Female Diabetic db/db Mice Independent …
  459. Rare Infection Linked With SGLT-2 inhibitor Use
  460. Unmasking Type–1 Diabetes Mellitus Following an Episode of Euglycemic Diabetic Ketoacidosis with SGLT-2 inhibitor Use: A Case Report
  461. A case series of sodium glucose co-transporter-2 inhibitor (SGLT-2i) related diabetic ketoacidosis and literature review of the possible pathophysiology
  462. Effect of SGLT-2 inhibitor Therapy on Cardiovascular Health in Diabetes Mellitus Patients
  463. Two clinical cases of adjunctive use of a SGLT-2 inhibitor in type 1 diabetes
  464. SUN-180 Successful Use of SGLT-2 inhibitor Dapagliflozin in Three Patients with Renal Transplant and Diabetes: A Fruit for Thoughts
  465. SGLT-2 inhibitor-INDUCED DKA: UNMASKING OF LATENT AUTOIMMUNE DIABETES IN ADULTS. CAN WE DO BETTER?
  466. Use of SGLT‐2 inhibitor in COVID‐19: A cautionary tale
  467. A Case of Euglycemic DKA With SGLT 2 inhibitor Use-A Diagnostic and Therapeutic Dilemma
  468. Severe SGLT-2 inhibitor-induced euglycemic ketoacidosis-a rare but serious complication
  469. 5.1 EFFECTS OF THE SGLT-2 inhibitor EMPAGLIFLOZIN ON VASCULAR FUNCTION AND CENTRAL HEMODYNAMICS IN PATIENTS WITH TYPE 2 …
  470. … agonist; empagliflozin (Jardiance®, Boehringer Ingelheim and Eli Lilly), a SGLT-2 inhibitor; and sitagliptin (Januvia®, Merck), a DPP-4 inhibitor. However, we do …
  471. BITTER-SWEET DKA: A CASE OF SGLT-2 inhibitor INDUCED EUGLYCEMIC DKA IN A TYPE-1 DIABETIC PATIENT
  472. SGLT 2 inhibitor induced euglycemic ketoacidosis
  473. BP reduction with the sodium glucose co-transporter 2 inhibitor (SGLT-2i) empagliflozin (EMPA) in type 2 diabetes (T2D) is similar in treatment naïve as in those on …
  474. The combinatorial effective approach of alpha-glucosidase inhibitor and Sodium-glucose co-transporter 2 (SGLT-2)
  475. Post-Operative Euglycemic Diabetic Ketoacidosis in a Patient With SGLT-2 inhibitor Use and Recent Sleeve Gastrectomy
  476. First‐dose effect of the SGLT 2 inhibitor ipragliflozin on cardiovascular activity in spontaneously diabetic Torii fatty rats
  477. Fournier’s gangrene and diabetic ketoacidosis with lower-than-anticipated glucose levels associated with SGLT-2 inhibitor: A double trouble
  478. Body weight gain and hyperphagia after administration of SGLT-2 inhibitor: a case report
  479. Acute interstitial nephritis related to SGLT-2 inhibitor
  480. … mechanisms underlying the renoprotective effect of empagliflozin, a novel selective sodium glucose co-transporter (SGLT) 2 inhibitor, against diabetic nephropathy in …
  481. Functional imaging of pharmacological action of SGLT2 inhibitor ipragliflozin via PET imaging using 11C‐MDG
  482. Euglycemic Diabetic Ketoacidosis in a Patient on a SGLT-2 inhibitor Presenting with Acute Pancreatitis
  483. Pharmacokinetics, Biotransformation, Distribution and Excretion of Empagliflozin, a Sodium-Glucose Co-Transporter (SGLT 2) inhibitor
  484. Dapagliflozin, the first SGLT-2 inhibitor in the treatment of type 2 diabetes
  485. Short-term renoprotective effect of SGLT-2 inhibitor for renal function and albuminuria in type 2 diabetes: a retrospective study
  486. Euglycemic Diabetic Ketoacidosis With SGLT-2 inhibitor
  487. Canagliflozin, a SGLT-2 inhibitor, relieves ER stress, modulates autophagy and induces apoptosis in irradiated HepG2 cells: Signal transduction between …
  488. Effects of concomitant combination of SGLT‐2 inhibitor and GLP‐1 receptor agonist on renal outcomes in T2D with eGFR below 30 and macroalbuminuria: A case …
  489. SHOULD CARDIOLOGIST PRESCRIBE AN SGLT-2 inhibitor?
  490. Short-term renoprotective effect of SGLT-2 inhibitor for renal function and albuminuria in type 2 diabetes
  491. Acute Renal Failure With Cocaine and SGLT-2 inhibitor
  492. GLP-1RA as Add-on Therapy to SGLT-2 inhibitor
  493. Improvement in glycaemic parameters using SGLT-2 inhibitor and GLP-1 agonist in combination in an adolescent with diabetes mellitus and Prader-Willi syndrome: a …
  494. Effect of SGLT-2 inhibitor on Bone Turnover in Overweight and Obese Patients with Type 2 Diabetes
  495. Choosing an SGLT-2 inhibitor for a patient with type 2 diabetes: Which agent (if any) is best
  496. Effect of tofogliflozin, a SGLT-2 inhibitor, on diabetic ocular complications in SDT rats
  497. Identification on Anti-Atherosclerotic Mechanism of SGLT-2 inhibitor in Diabetic Rabbit Model
  498. Upregulation of Toll-Like Receptors That Underlies Diabetes-Induced Exacerbation of Cardiorenal Syndrome is Attenuated by Canagliflozin, an SGLT-2 inhibitor
  499. Effects of Combination of SGLT-2 inhibitor and GLP-1 Receptor Agonist on Renal Outcome in T2D with GFR below 30 and Macroalbuminuria: A Case Series
  500. Hyperglycemic Diabetic ketoacidosis precipitated by an SGLT-2 inhibitor in a non-insulin dependant type 2 diabetic
  501. Effects of SGLT-2 inhibitor on mitochondrial function in renal proximal tubular cell
  502. SGLT-2 inhibitor: A Unique Antidiabetic in Type 2 Diabetes Mellitus
  503. Sodium dependent glucose transporter (SGLT) 1/2-elucidating inhibitor SAR and selectivity using homology modelling and 3D QSAR studies.
  504. Euglycemic DKA after initiating an SGLT-2 inhibitor and the P90X diet
  505. Effect of dual sodium-glucose cotransporter (SGLT)-1/2 inhibitor sotagliflozin on glycemic and nonglycemic outcomes and on hypoglycemia in type 1 diabetes. A meta …
  506. Farxiga (Dapagliflozin), an Oral SGLT-2 inhibitor, a New FDA-Approved Treatment Option for Type 2 Diabetes
  507. Hydrogen-bonded structures and interaction energies in two forms of the SGLT-2 inhibitor sotagliflozin
  508. Dapagliflozin (forxiga®): SGLT 2 cotransporter inhibitor as glucose-lowering agent in type 2 diabetes
  509. Ketoacidosis with SGLT-2 inhibitor and Ketogenic Diet: A Case Study
  510. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review
  511. SGLT2 inhibitors may predispose to ketoacidosis
  512. An update on the safety of SGLT2 inhibitors
  513. SGLT2 inhibitors: are they safe?
  514. Update on developments with SGLT2 inhibitors in the management of type 2 diabetes
  515. Possible adverse effects of SGLT2 inhibitors on bone
  516. A review on the relationship between SGLT2 inhibitors and cancer
  517. SGLT2 inhibitors and the diabetic kidney
  518. Risks associated with SGLT2 inhibitors: an overview
  519. SGLT2 inhibitors
  520. An update on SGLT2 inhibitors for the treatment of diabetes mellitus
  521. SGLT2 inhibitors and mechanisms of hypertension
  522. The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure
  523. The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus
  524. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis
  525. Development of SGLT1 and SGLT2 inhibitors
  526. Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits
  527. Effects of SGLT2 inhibitors on cardiovascular outcomes
  528. Direct cardiovascular impact of SGLT2 inhibitors: mechanisms and effects
  529. SGLT2 inhibitors: their potential reduction in blood pressure
  530. SGLT2 inhibitors as a therapeutic option for diabetic nephropathy
  531. Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans
  532. SGLT2 inhibitors in the treatment of type 2 diabetes
  533. Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors
  534. SGLT2 inhibitors: the latest “new kids on the block”!
  535. Cardiac effects of SGLT2 inhibitors: the sodium hypothesis
  536. SGLT2 inhibitors: molecular design and potential differences in effect
  537. Acute kidney injury in patients on SGLT2 inhibitors: a propensity-matched analysis
  538. SGLT2 inhibitors: hypotheses on the mechanism of cardiovascular protection
  539. Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors
  540. SGLT2 inhibitors: benefit/risk balance
  541. Acute kidney injury from SGLT2 inhibitors: potential mechanisms
  542. Promise of SGLT2 inhibitors in heart failure: diabetes and beyond
  543. Pump, pipes, and filter: do SGLT2 inhibitors cover it all?
  544. Mechanisms and evidence for heart failure benefits from SGLT2 inhibitors
  545. Metabolism of the failing heart and the impact of SGLT2 inhibitors
  546. Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30–50% of filtered glucose load in humans
  547. Lower risk of death with SGLT2 inhibitors in observational studies: real or bias?
  548. SGLT2 inhibitors in the management of type 2 diabetes
  549. Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis
  550. Why do SGLT2 inhibitors inhibit only 30–50% of renal glucose reabsorption in humans?
  551. Uric acid and the cardio‐renal effects of SGLT2 inhibitors
  552. SGLT2 inhibitors-induced electrolyte abnormalities: an analysis of the associated mechanisms
  553. The potential role of SGLT2 inhibitors in the treatment of type 1 diabetes mellitus
  554. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of …
  555. SGLT2 inhibitors: a review of their antidiabetic and cardioprotective effects
  556. Efficacy and safety of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus
  557. SGLT2 inhibitors in combination therapy: from mechanisms to clinical considerations in type 2 diabetes management
  558. Synthetic strategies toward SGLT2 inhibitors
  559. SGLT2 inhibitors and the kidney: effects and mechanisms
  560. Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis
  561. SGLT2 inhibitors and cardiovascular risk: lessons learned from the EMPA-REG OUTCOME study
  562. Practical approach to initiating SGLT2 inhibitors in type 2 diabetes
  563. SGLT2 inhibitors: a new emerging therapeutic class in the treatment of type 2 diabetes mellitus
  564. SGLT2 inhibitors in patients with type 2 diabetes and renal disease: overview of current evidence
  565. The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments
  566. Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: the potential contribution to diabetes complications and cardiovascular disease
  567. Are SGLT2 inhibitors ready for prime time for CKD?
  568. The renal effects of SGLT2 inhibitors and a mini-review of the literature
  569. Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and …
  570. Amelioration of diabetic nephropathy by SGLT2 inhibitors independent of its glucose-lowering effect: A possible role of SGLT2 in mesangial cells
  571. SGLT2 inhibitors and cardioprotection: a matter of debate and multiple hypotheses
  572. Mechanistic insights regarding the role of SGLT2 inhibitors and GLP1 agonist drugs on cardiovascular disease in diabetes
  573. A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity
  574. Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: basic mechanisms and therapeutic perspectives
  575. Pharmacokinetics, pharmacodynamics and clinical use of SGLT2 inhibitors in patients with type 2 diabetes mellitus and chronic kidney disease
  576. SGLT2 inhibitors and amputations in the US FDA Adverse Event Reporting System
  577. Effects of SGLT2 inhibitors on cardiovascular outcomes and mortality in type 2 diabetes: a meta-analysis
  578. SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease
  579. SGLT2 inhibitors in type 2 diabetes management: key evidence and implications for clinical practice
  580. SGLT2 inhibitors: the future for treatment of type 2 diabetes mellitus and other chronic diseases
  581. Evaluating SGLT2 inhibitors for type 2 diabetes: pharmacokinetic and toxicological considerations
  582. Effect of SGLT2 inhibitors on the sympathetic nervous system and blood pressure
  583. The serendipitous story of SGLT2 inhibitors in heart failure: new insights from DECLARE-TIMI 58
  584. Efficacy, safety and regulatory status of SGLT2 inhibitors: focus on canagliflozin
  585. SGLT2 inhibitors increase the risk of diabetic ketoacidosis developing in the community and during hospital admission
  586. Mechanisms in endocrinology: SGLT2 inhibitors: clinical benefits by restoration of normal diurnal metabolism?
  587. SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials
  588. SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System
  589. Does lower limb amputation concern all SGLT2 inhibitors?
  590. SGLT2 inhibitors as adjunctive therapy for type 1 diabetes: balancing benefits and risks
  591. Adverse effects of SGLT2 inhibitors on bone health
  592. Empagliflozin increases cardiac energy production in diabetes: novel translational insights into the heart failure benefits of SGLT2 inhibitors
  593. Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: a common comorbidity associated with severe complications
  594. Acute kidney injury and adverse renal events in patients receiving SGLT2–inhibitors: a systematic review and meta-analysis
  595. SGLT2 inhibitors: cardiovascular benefits beyond HbA1c—translating evidence into practice
  596. SGLT2 inhibitors: nephroprotective efficacy and side effects
  597. SGLT2 inhibitors: β blockers for the kidney?
  598. Adoption of new glucose-lowering medications in the US—the case of SGLT2 inhibitors: nationwide cohort study
  599. Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non‐SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with …
  600. SGLT2 inhibitors and risk of stroke in patients with type 2 diabetes: A systematic review and meta‐analysis
  601. Use of SGLT2 inhibitors for diabetes and risk of infection: analysis using general practice records from the NPS MedicineWise MedicineInsight program
  602. Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind …
  603. SGLT2 inhibitors in T2D and associated comorbidities—differentiating within the class
  604. Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data
  605. SGLT2 inhibitors with cardiovascular benefits: transforming clinical care in type 2 diabetes mellitus
  606. SGLT2 inhibitors: glucuretic treatment for type 2 diabetes
  607. Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney …
  608. The efficacy and safety of SGLT2 inhibitors for adjunctive treatment of type 1 diabetes: a systematic review and meta-analysis
  609. SGLT2 inhibitors: a promising new therapeutic option for treatment of type 2 diabetes mellitus
  610. Cardiovascular and renal benefits of SGLT2 inhibitors: a narrative review
  611. Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation
  612. Characterization and comparison of SGLT2 inhibitors: Part 3. Effects on diabetic complications in type 2 diabetic mice
  613. SGLT2 inhibitors for the treatment of diabetes: a patent review (2013-2018)
  614. SGLT2 inhibitors and renal outcomes in type 2 diabetes with or without renal impairment: a systematic review and meta-analysis
  615. Effect of SGLT2 inhibitors on body composition, fluid status and renin–angiotensin–aldosterone system in type 2 diabetes: a prospective study using …
  616. Increases in circulating levels of ketone bodies and cardiovascular protection with SGLT2 inhibitors: Is low‐grade inflammation the neglected component?
  617. SGLT2 inhibitors and urinary tract infections
  618. Efficacy and renal outcomes of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease
  619. Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models
  620. Safety of SGLT2 inhibitors in patients with diabetes mellitus
  621. Lessons learned from the DAPA-HF trial concerning the mechanisms of benefit of SGLT2 inhibitors on heart failure events in the context of other large-scale …
  622. SGLT2 inhibitors through the windows of EMPA-REG and CANVAS trials: a review
  623. Combined SGLT1 and SGLT2 inhibitors and their role in diabetes care
  624. Effects of SGLT2 inhibitors on fractures and bone mineral density in type 2 diabetes: An updated meta‐analysis
  625. Effects of SGLT2 inhibitors on weight loss in patients with type 2 diabetes mellitus
  626. SGLT2 inhibitors and diabetic ketoacidosis—a growing concern
  627. Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta‐analysis
  628. The role of kidney in glucose homeostasis–SGLT2 inhibitors, a new approach in diabetes treatment
  629. SGLT2 inhibitors: New medicines for addressing unmet needs in type 2 diabetes
  630. SGLT2 inhibitors–an insulin-independent therapeutic approach for treatment of type 2 diabetes: focus on canagliflozin
  631. The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system
  632. Risk of amputations associated with SGLT2 inhibitors compared to DPP‐4 inhibitors: a propensity‐matched cohort study
  633. SGLT2 inhibitors and cardiovascular outcomes: current perspectives and future potentials
  634. SGLT2 inhibitors and metformin: Dual antihyperglycemic therapy and the risk of metabolic acidosis in type 2 diabetes
  635. The role of the kidney and SGLT2 inhibitors in type 2 diabetes
  636. Effectiveness of long-term treatment with SGLT2 inhibitors: real-world evidence from a specialized diabetes center
  637. Are SGLT2 inhibitors reasonable antihypertensive drugs and renoprotective?
  638. Renoprotective effects of GLP1R agonists and SGLT2 inhibitors
  639. SGLT2 inhibitors: practical considerations and recommendations for cardiologists
  640. Discovery of non-glucoside SGLT2 inhibitors
  641. Positioning SGLT2 inhibitors/incretin-based therapies in the treatment algorithm
  642. Weight loss variability with SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes mellitus and obesity: mechanistic possibilities
  643. Meta-analyses of the effects of DPP-4 inhibitors, SGLT2 inhibitors and GLP1 receptor analogues on cardiovascular death, myocardial infarction, stroke and …
  644. SGLT2 inhibitors‘ interaction with other renoactive drugs in type 2 diabetes patients: still a lot to learn
  645. Cardiorenal protection: potential of SGLT2 inhibitors and GLP-1 receptor agonists in the treatment of type 2 diabetes
  646. Role of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus
  647. Clinical implication of SGLT2 inhibitors in type 2 diabetes
  648. Potential impact of SGLT2 inhibitors on left ventricular diastolic function in patients with diabetes mellitus
  649. ACE and SGLT2 inhibitors: the future for non-diabetic and diabetic proteinuric renal disease
  650. SGLT2–inhibitors: a novel class for the treatment of type 2 diabetes introduction of SGLT2–inhibitors in clinical practice
  651. SGLT2 inhibitors to control glycemia in type 2 diabetes mellitus: a new approach to an old problem
  652. SGLT2 inhibitors in the pipeline for the treatment of diabetes mellitus in Japan
  653. Mechanisms of protective effects of SGLT2 inhibitors in cardiovascular disease and renal dysfunction
  654. SGLT2 inhibitors for diabetes: turning symptoms into therapy.
  655. Effects of SGLT2 inhibitors on circulating stem and progenitor cells in patients with type 2 diabetes
  656. Design of SGLT2 inhibitors for the treatment of type 2 diabetes: a history driven by biology to chemistry
  657. The expanding résumé of SGLT2 inhibitors
  658. Cardioprotective effects of SGLT2 inhibitors are possibly associated with normalization of the circadian rhythm of blood pressure
  659. Renoprotective effects of SGLT2 inhibitors: beyond glucose reabsorption inhibition
  660. Benefits of SGLT2 inhibitors beyond glycemic control–a focus on metabolic, cardiovascular and renal outcomes
  661. Update on SGLT2 inhibitors—new data released at the American Diabetes Association
  662. Generalizability of cardiovascular safety trials on SGLT2 inhibitors to the real world: implications for clinical practice
  663. Efficacy of SGLT2 inhibitors in glycemic control, weight loss and blood pressure reduction: a systematic review and meta-analysis
  664. Emerging roles of SGLT2 inhibitors in obesity and insulin resistance: Focus on fat browning and macrophage polarization
  665. Clinical characteristics of diabetic ketoacidosis in users and non-users of SGLT2 inhibitors
  666. Blood pressure effects of sodium–glucose co-transport 2 (SGLT2) inhibitors
  667. The impact of SGLT2 inhibitors, compared with insulin, on diabetic bone disease in a mouse model of type 1 diabetes
  668. Sodium glucose CoTransporter 2 (SGLT2) inhibitors: Current status and future perspective
  669. Novel C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents: 1, 3, 4-thiadiazolylmethylphenyl glucoside congeners
  670. SGLT2 inhibitors and incretin agents: associations with alanine aminotransferase activity in type 2 diabetes
  671. SGLT2 inhibitors in type 1 diabetes: knocked down, but up again?
  672. Can SGLT2 inhibitors cause acute renal failure? Plausible role for altered glomerular hemodynamics and medullary hypoxia
  673. Efficacy and safety of SGLT2 inhibitors in patients with type 1 diabetes: a meta-analysis of randomized controlled trials
  674. The role of SGLT2 inhibitors in managing type 2 diabetes
  675. SGLT2 inhibitors and cancer: why further evidence is required
  676. Sodium glucose co-transporter-2 (SGLT2) inhibitors: a review of their basic and clinical pharmacology
  677. Pharmacodynamics, efficacy and safety of sodium–glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus
  678. Synthesis of pyridazine and thiazole analogs as SGLT2 inhibitors
  679. Potential hypoxic renal injury in patients with diabetes on SGLT2 inhibitors: caution regarding concomitant use of NSAIDs and iodinated contrast media
  680. SGLT2 inhibitors and risk of genitourinary infections
  681. The effect of SGLT2 inhibitors on cardiovascular events and renal function
  682. SGLT1 in pancreatic α cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels
  683. The design and synthesis of novel SGLT2 inhibitors: C-glycosides with benzyltriazolopyridinone and phenylhydantoin as the aglycone moieties
  684. Are SGLT2 inhibitors a targeted treatment for diabetic kidney disease?
  685. Sodium glucose co-transporter type 2 (SGLT2) inhibitors: targeting the kidney to improve glycemic control in diabetes mellitus
  686. SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectives
  687. Ipragliflozin and other sodium–glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data
  688. Combination treatment of SGLT2 inhibitors and GLP-1 receptor agonists: symbiotic effects on metabolism and cardiorenal risk
  689. Turning glucosuria into a therapy: Efficacy and safety with SGLT2 inhibitors
  690. Reduction of cardiovascular risk and improved estimated glomerular filtration rate by SGLT2 inhibitors, including dapagliflozin, is consistent across the class: an …
  691. How and why SGLT2 inhibitors should be explored as potential treatment option in diabetic retinopathy: clinical concept and methodology
  692. A new HPLC–MS/MS method for the simultaneous quantification of SGLT2 inhibitors and metformin in plasma and its application to a pharmacokinetic study in healthy …
  693. … -glucose cotransporter-2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and dipeptidyl peptidase-4 (DPP-4) inhibitors: a systematic review
  694. SGLT2 inhibitors in the real world: too good to be true?
  695. Sodium-glucose cotransporter-2 (SGLT2) inhibitors: a clinician’s guide
  696. Effects of sodium‐glucose co‐transporter 2 (SGLT2) inhibitors on serum uric acid level: a meta‐analysis of randomized controlled trials
  697. SGLT2 inhibitors and protection against pancreatic beta cell failure
  698. Fluorine‐Directed Glycosylation Enables the Stereocontrolled Synthesis of Selective SGLT2 inhibitors for Type II Diabetes
  699. Euglycemic diabetic ketoacidosis: The clinical concern of SGLT2 inhibitors
  700. A fluorescent glucose transport assay for screening SGLT2 inhibitors in endogenous SGLT2-expressing HK-2 cells
  701. Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis
  702. SGLT2 inhibitors as add on therapy in type 2 diabetes: a real world study
  703. SGLT2 inhibitors and heart failure—clinical implications
  704. Synthesis and biological evaluation of SGLT2 inhibitors: gem-difluoromethylenated Dapagliflozin analogs
  705. The major molecular mechanisms mediating the renoprotective effects of SGLT2 inhibitors: An update
  706. Use of SGLT2 inhibitors during Ramadan: a survey of physicians’ views and practical guidance
  707. SGLT2 inhibitors in Type 1 diabetes: is this the future?
  708. A paradigm shift in diabetes therapy—dapagliflozin and other SGLT2 inhibitors
  709. An update of SGLT1 and SGLT2 inhibitors in early phase diabetes-type 2 clinical trials
  710. Sodium‐glucose cotransporter 2 (SGLT2) inhibitors and fracture risk in patients with type 2 diabetes mellitus: a meta‐analysis
  711. SGLT2 inhibitors race to enter type-2 diabetes market
  712. Synthesis and biological evaluation of C-glucosides with azulene rings as selective SGLT2 inhibitors for the treatment of type 2 diabetes mellitus: Discovery of YM543
  713. SGLT2 inhibitors: reviving the sodium-hydrogen exchanger cardioprotection hypothesis?
  714. Case reports that illustrate the efficacy of SGLT2 inhibitors in the type 1 diabetic patient
  715. How representative of a general type 2 diabetes population are patients included in cardiovascular outcome trials with SGLT2 inhibitors? A large European …
  716. Facile synthesis of 1, 2, 3-triazole analogs of SGLT2 inhibitors by ‘click chemistry’
  717. Type 2 diabetes, SGLT2 inhibitors, and glucose secretion
  718. The potential of SGLT2 inhibitors in phase II clinical development for treating type 2 diabetes
  719. The cardiovascular safety trials of DPP-4 inhibitors, GLP-1 agonists, and SGLT2 inhibitors
  720. Potential place of SGLT2 inhibitors in treatment paradigms for type 2 diabetes mellitus
  721. Analysis of the efficacy of SGLT2 inhibitors using semi-mechanistic model
  722. Evaluating drug cost per response with SGLT2 inhibitors in patients with type 2 diabetes mellitus
  723. Novel C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents: Pyridazinylmethylphenyl glucoside congeners
  724. SGLT2 inhibitors—Sweet Success for Diabetic Kidney Disease?
  725. Recent developments of C-aryl glucoside SGLT2 inhibitors
  726. SGLT2 inhibitors in development
  727. Lack of evidence for a harmful effect of sodium‐glucose co‐transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative …
  728. … of SGLT2 and SGLT1: a quantitative systems pharmacology analysis in healthy individuals and patients with type 2 diabetes treated with SGLT2 inhibitors
  729. Use of flash glucose monitoring system in assessing safety of the SGLT2 inhibitors during Ramadan fasting in high risk insulin treated patients with type 2 diabetes
  730. SGLT2 inhibitors and amputation risk: Real-world data from a diabetes foot wound clinic
  731. Novel thiophenyl C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents
  732. SGLT2 inhibitors and the risk of diabetic ketoacidosis
  733. Synthesis and SAR of Thiazolylmethylphenyl Glucoside as Novel C-Aryl Glucoside SGLT2 inhibitors
  734. … involvement of normalized Pin1 expression level and AMPK activation in the molecular mechanisms underlying renal protective effects of SGLT2 inhibitors in …
  735. Role of SGLT2 inhibitors in patients with diabetes mellitus and heart failure
  736. Sodium glucose transport 2 (SGLT2) inhibition decreases glomerular hyperfiltration: is there a role for SGLT2 inhibitors in diabetic kidney disease?
  737. Comparative risk of genital infections associated with SGLT2 inhibitors: a real-world retrospective cohort study
  738. SGLT2 inhibitors and cirrhosis: A unique perspective on the comanagement of diabetes mellitus and ascites
  739. How does CREDENCE inform best use of SGLT2 inhibitors in CKD?
  740. Effects of incretin-based therapies and SGLT2 inhibitors on skeletal health
  741. Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agents
  742. Sodium-glucose cotransporter 2 (SGLT2) inhibitors from natural products: discovery of next-generation antihyperglycemic agents
  743. What next after metformin? Thinking beyond glycaemia: are SGLT2 inhibitors the answer?
  744. Design, synthesis and in vivo hypoglycemic activity of tetrazole-bearing N-glycosides as SGLT2 inhibitors
  745. Efficacy and safety of GLP-1 receptor agonists as add-on to SGLT2 inhibitors in type 2 diabetes mellitus: A meta-analysis
  746. Sodium glucose co-transporter 2 (SGLT2) inhibitors as potential antidiabetic agents
  747. Sodium-glucose linked transporter 2 (SGLT2) inhibitors in the management of type-2 diabetes: a drug class overview
  748. Safety and efficacy of sodium-glucose cotransporter 2 (SGLT2) inhibitors in type 1 diabetes: A systematic review and meta-analysis
  749. The potential of sodium glucose cotransporter 2 (SGLT2) inhibitors to reduce cardiovascular risk in patients with type 2 diabetes (T2DM)
  750. Promising diabetes therapy based on the molecular mechanism for glucose toxicity: usefulness of SGLT2 inhibitors as well as incretin-related drugs
  751. Clinical potential relevance of metabolic properties of SGLT2 inhibitors in patients with heart failure
  752. Cardiovascular outcome studies in type 2 diabetes: comparison between SGLT2 inhibitors and GLP-1 receptor agonists
  753. SGLT2 inhibitors might halt progression of diabetic nephropathy
  754. Incidence of diabetic ketoacidosis among patients with type 2 diabetes mellitus treated with SGLT2 inhibitors and other antihyperglycemic agents
  755. Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
  756. Further insights into SGLT2 inhibitors
  757. Diabetic ketoacidosis precipitated by therapy with antidiabetic agents SGLT2 inhibitors: two cases
  758. A comparative safety review between GLP-1 receptor agonists and SGLT2 inhibitors for diabetes treatment
  759. 12-month effects of incretins versus SGLT2–inhibitors on cognitive performance and metabolic profile. A randomized clinical trial in the elderly with Type-2 …
  760. Optimization of triazoles as novel and potent nonphlorizin SGLT2 inhibitors
  761. SGLT2 inhibitors and GLP-1 receptor agonists: a sound combination
  762. Pyrimidinylmethylphenyl glucoside as novel C-aryl glucoside SGLT2 inhibitors
  763. The kidney and type 2 diabetes mellitus: therapeutic implications of SGLT2 inhibitors
  764. Clinical implications of current cardiovascular outcome trials with sodium glucose cotransporter-2 (SGLT2) inhibitors
  765. Pleiotropic effects of SGLT2 inhibitors beyond the effect on glycemic control
  766. Effects of reducing blood pressure on cardiovascular outcomes and mortality in patients with type 2 diabetes: focus on SGLT2 inhibitors and EMPA-REG OUTCOME
  767. Design and synthesis of fluorescent SGLT2 inhibitors
  768. CoMFA and CoMSIA studies on C-aryl glucoside SGLT2 inhibitors as potential anti-diabetic agents
  769. Drug–drug interactions with sodium-glucose cotransporters type 2 (SGLT2) inhibitors, new oral glucose-lowering agents for the management of type 2 diabetes …
  770. Effect of SGLT2 inhibitors in a murine model of urinary tract infection with Candida albicans
  771. Novel l-Xylose Derivatives as Selective Sodium-Dependent Glucose Cotransporter 2 (SGLT2) inhibitors for the Treatment of Type 2 Diabetes
  772. C-Aryl glucoside SGLT2 inhibitors containing a biphenyl motif as potential anti-diabetic agents
  773. How many patients with type 2 diabetes meet the inclusion criteria of the cardiovascular outcome trials with SGLT2 inhibitors? Estimations from a population …
  774. Use of SGLT2 inhibitors in diabetic renal transplant recipients: a mixed method exploratory exercise
  775. Pharmacoeconomic evaluation of sodium-glucose transporter-2 (SGLT2) inhibitors for the treatment of type 2 diabetes
  776. Glycosylated dihydrochalcones as potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitors
  777. SGLT2 inhibitors for type 2 diabetes
  778. When insulin therapy fails: the impact of SGLT2 inhibitors in patients with type 2 diabetes
  779. SGLT2 inhibitors enter crowded diabetes space
  780. Novel macrocyclic C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents
  781. Development of a novel non-radioactive cell-based method for the screening of SGLT1 and SGLT2 inhibitors using 1-NBDG
  782. Preventing diabetic renal disease: the potential reno-protective effects of SGLT2 inhibitors
  783. Efficacy of DPP‐4 inhibitors, GLP‐1 analogues, and SGLT2 inhibitors as add‐ons to metformin monotherapy in T2DM patients: a model‐based meta‐analysis
  784. SGLT2 inhibitors: glucotoxicity and tumorigenesis downstream the renal proximal tubule?
  785. Circadian blood pressure rhythm as a possible key target of SGLT2 inhibitors used for the treatment of type 2 diabetes
  786. Targeting Type 2 Diabetes with C-Glucosyl Dihydrochalcones as Selective Sodium Glucose Co-Transporter 2 (SGLT2) inhibitors: Synthesis and Biological Evaluation
  787. Effects of sodium-glucose co-transporter-2 (SGLT2) inhibitors on non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Ex quo et quo vadimus?
  788. 1224-P: Improving compliance with SGLT2 inhibitors by reducing the risk of genital mycotic infections: the outcomes of personal hygiene advice
  789. Effects of reducing blood pressure on renal outcomes in patients with type 2 diabetes: focus on SGLT2 inhibitors and EMPA-REG OUTCOME
  790. Discovery of Novel N-β-d-Xylosylindole Derivatives as Sodium-Dependent Glucose Cotransporter 2 (SGLT2) inhibitors for the Management of Hyperglycemia in …
  791. Renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for new anti-diabetic agent
  792. Sodium glucose co-transporter 2 (SGLT2) inhibitors: novel antidiabetic agents
  793. Efficacy and safety of SGLT2 inhibitors in reducing glycated hemoglobin and weight in emirati patients with type 2 diabetes
  794. Exploration of O-spiroketal C-arylglucosides as novel and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors
  795. SGLT2–inhibitors trigger downstream mechanisms that may exert adverse effects upon bone
  796. Remarkable improvement of glucose variability by Sodium–glucose cotransporter 2 (SGLT2) inhibitors using continuous glucose monitoring (CGM)
  797. SGLT2 inhibitors-moving on with the evidence.
  798. Chances and risks of SGLT2 inhibitors
  799. Thiazolylmethyl ortho-substituted phenyl glucoside library as novel C-aryl glucoside SGLT2 inhibitors
  800. … to serious skin and subcutaneous tissue disorders and skin tissue distribution of sodium-dependent glucose co-transporter type 2 (SGLT2) inhibitors
  801. Synthesis and biological evaluation of novel tetrahydroisoquinoline-C-aryl glucosides as SGLT2 inhibitors for the treatment of type 2 diabetes
  802. Atom-based 3D QSAR studies on novel N-β-d-xylosylindole derivatives as SGLT2 inhibitors
  803. Sodium-glucose cotransporter 2 (SGLT2) inhibitors and cardiovascular disease: a systematic review
  804. Type 2 sodium-glucose cotransporter (SGLT2) inhibitors: from familial renal glucosuria to the treatment of type 2 diabetes mellitus
  805. Assessment of the benefit-risk balance of SGLT2 inhibitors: Commentary on a new’French paradox’.
  806. Sodium glucose co transporter 2 (SGLT2) inhibitors: a new sword for the treatment of type 2 diabetes mellitus
  807. Indole-glucosides as novel sodium glucose co-transporter 2 (SGLT2) inhibitors. Part 2
  808. Can the combination of incretin agents and sodium-glucose cotransporter 2 (SGLT2) inhibitors reconcile the Yin and Yang of glucagon?
  809. SGLT2 inhibitors and the changing landscape for treatment of diabetes
  810. Glucosides with cyclic diarylpolynoid as novel C-aryl glucoside SGLT2 inhibitors
  811. Syntheses of C-5-spirocyclic C-glycoside SGLT2 inhibitors
  812. Safety of SGLT2 inhibitors. A review of the adverse drug reactions registered in a national database
  813. Recent and emerging therapeutic medications in type 2 diabetes mellitus: incretin-based, pramlintide, colesevelam, SGLT2 inhibitors, tagatose, succinobucol
  814. Will SGLT2 inhibitors prove to be a ‘multiple’gamechanger?
  815. Sodium glucose co-transporter 2 (SGLT2) inhibitors: new among antidiabetic drugs
  816. When metformin is not enough: Pros and cons of SGLT2 and DPP‐4 inhibitors as a second line therapy
  817. Diuretic treatment of the patient with diabetes and heart failure. Role of SGLT2 inhibitors and similarities with carbonic anhydrase inhibitors
  818. Optimization of Gaussian Kernel Function in Support Vector Machine aided QSAR studies of C-aryl glucoside SGLT2 inhibitors
  819. Response to comment on Suissa. Lower risk of death with SGLT2 inhibitors in observational studies: real or bias? Diabetes Care 2018; 41: 6–10
  820. Discovery of non-glycoside sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors by ligand-based virtual screening
  821. Role of metformin, Sodium-Glucose Cotransporter-2 (SGLT2) inhibitors, Glucagon-Like Peptide-1 (GLP-1) receptor agonists, and orlistat based multidrug …
  822. Essentials of SGLT2 inhibitors in Diabetes
  823. Design, synthesis and biological activity of cyclohexane-bearing C-glucoside derivatives as SGLT2 inhibitors
  824. Possible new inflammatory side-effect of SGLT2–inhibitors: fixed drug eruption
  825. A rose by any other name: ketoacidosis due to SGLT2 inhibitors reveals latent autoimmune diabetes
  826. Are SGLT2 inhibitors or GLP-1 receptor agonists more appropriate as a second-line therapy in type 2 diabetes?
  827. Palladium‐Catalyzed Arylation of Carbasugars Enables the Discovery of Potent and Selective SGLT2 inhibitors
  828. Renal and cardiac implications of sodium glucose cotransporter 2 (SGLT2) inhibitors: the state of the science
  829. Thiadiazole‐based thioglycosides as sodium‐glucose co‐transporter 2 (SGLT2) inhibitors
  830. O-Spiro C-aryl glucosides as novel sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors
  831. SGLT2 inhibitors provide an effective therapeutic option for diabetes complicated with insulin antibodies
  832. C-Aryl glycoside inhibitors of SGLT2: Exploration of sugar modifications including C-5 spirocyclization
  833. Unsweetening the heart: possible pleiotropic effects of SGLT2 inhibitors on cardio and cerebrovascular alterations in resistant hypertensive subjects
  834. ortho-Substituted C-aryl glucosides as highly potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors
  835. SGLT2 versus DPP4 inhibitors for type 2 diabetes
  836. … and biological evaluation of 6-deoxy O-spiroketal C-arylglucosides as novel renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of …
  837. Drugs for diabetes: part 8 SGLT2 inhibitors
  838. SGLT2 inhibitors in diabetes mellitus treatment
  839. 5a-Carba-β-d-glucopyranose derivatives as novel sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes
  840. The Efficacy of Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors for the treatment of chronic diabetic macular oedema in vitrectomised eyes: a retrospective study
  841. A specific pharmacophore model of sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors
  842. Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes
  843. Bolstering your armamentarium with SGLT2 inhibitors
  844. Sweet success? SGLT2 inhibitors and diabetes
  845. Conformationally Constrained Spiro C‐Arylglucosides as Potent and Selective Renal Sodium‐Dependent Glucose Co‐transporter 2 (SGLT2) inhibitors
  846. Potential role of SGLT2 inhibitors in the management of type 1 diabetes
  847. SGLT2 inhibitors suppress NLRP3 inflammasome activity via changes in ketones and insulin in type 2 diabetes and cardiovascular diseases
  848. C-Aryl 5a-carba-β-D-glucopyranosides as novel sodium glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes
  849. Design, synthesis and in vivo anti-hyperglycemic activity of gem-dimethyl-bearing C-glucosides as SGLT2 inhibitors
  850. Sodium-glucose linked transporter 2 (SGLT2) inhibitors—fighting diabetes from a new perspective
  851. Repurposing SGLT2 inhibitors
  852. Sodium glucose transporter 2 (SGLT2) inhibitors: Current status in clinical practice.
  853. Synthesis and biological evaluation of novel dioxa-bicycle C-aryl glucosides as SGLT2 inhibitors
  854. Development of sodium glucose co-transporter 2 (SGLT2) inhibitors with novel structure by molecular docking and dynamics simulation
  855. Combined HQSAR, topomer CoMFA, homology modeling and docking studies on triazole derivatives as SGLT2 inhibitors
  856. How low do we fall to lower hemoglobin A1c? SGLT2 inhibitors: Effective drugs or expensive toxins!
  857. SGLT2 inhibitors for type 2 diabetes mellitus treatment
  858. … now on the CANVAS of diabetes medications with cardiovascular protection? Could metformin, pioglitazone, SGLT2 inhibitors and liraglutide complement …
  859. Apple trees to sodium glucose co-transporter inhibitors: a review of SGLT2 inhibition
  860. Predicting the biological activities of triazole derivatives as SGLT2 inhibitors using multilayer perceptron neural network, support vector machine, and projection …
  861. A Systematic Review of Analytical Profiles of SGLT2 inhibitors and their Combinations for Treatment of Type 2 Diabetes Mellitus
  862. Synthesis and biological evaluation of 6-hydroxyl C-aryl glucoside derivatives as novel sodium glucose co-transporter 2 (SGLT2) inhibitors
  863. SGLT2 inhibitors for treatment of type 2 diabetes mellitus: Focus on canagliflozin
  864. Heart Failure Prevention with SGLT2 inhibitors
  865. SGLT2 inhibitors: a new generation of antidiabetic drugs
  866. Effects of SGLT2 inhibitors on Renin-Aldosterone System for One Month and Six Months in Type 2 Diabetes
  867. Synthetic and biological studies of carbasugar SGLT2 inhibitors
  868. SGLT2 inhibitors Therapy in Type 2 Diabetes Mellitus
  869. Acidosis without marked hyperglycemia: Euglycemic diabetic ketoacidosis associated with SGLT2–inhibitors
  870. Development of a method to study the activity and selectivity of SGLT2 inhibitors
  871. A new and improved process for C-aryl glucoside SGLT2 inhibitors
  872. C-Aryl glucosides substituted at the 4′-position as potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors for the treatment of type …
  873. Diabetic ketoacidosis without hyperglycemia as a complication of SGLT2 inhibitors treatment
  874. Diabetic euglycemic ketosis or ketoacidosis in individuals with type 2 diabetes treated by SGLT2 inhibitors: A series of Belgian clinical cases
  875. Correction to “Synthetic Strategies toward SGLT2 inhibitors”
  876. … with cardiovascular protection after HARMONY Outcomes and DECLARE-TIMI 58: could metformin, pioglitazone, SGLT2 inhibitors and long-acting GLP-1 …
  877. SUN-177 house of Carbs: the path to euglycemic Dka in patients with diabetes on SGLT2 inhibitors
  878. β-Selective C-Arylation of Silyl Protected 1,6-Anhydroglucose with Arylalanes: The Synthesis of SGLT2 inhibitors
  879. Aglycone exploration of C-arylglucoside inhibitors of renal sodium-dependent glucose transporter SGLT2
  880. Heart Failure Endpoints in Cardiovascular Outcome Trials of SGLT2 inhibitors in Patients with Type 2 Diabetes: A Critical Evaluation of Clinical and …
  881. SGLT2 inhibitors: A Review of Canagliflozin
  882. SGLT2 inhibitors: rationale and perspectives of use in heart failure
  883. P2484 SGLT2 inhibitors in diabetes with CKD
  884. Comment on Suissa. Lower Risk of Death With SGLT2 inhibitors in Observational Studies: Real or Bias? Diabetes Care 2018; 41: 6–10
  885. SGLT2 inhibitors: not just another glucose-lowering agent
  886. SGLT2 inhibitors: Far too many cautions and alerts and limited efficacy
  887. An evaluation of US patent 2015065565 (A1) for a new class of SGLT2 inhibitors for treatment 1 of type II diabetes mellitus
  888. Synthesis and SAR of Benzisothiazole- and Indolizine-β-d-glucopyranoside inhibitors of SGLT2
  889. Development and application of a fluorescent glucose uptake assay for the high-throughput screening of non-glycoside SGLT2 inhibitors
  890. Effect of sodium glucose cotransporter 2 inhibitors with low SGLT2/SGLT1 selectivity on circulating glucagon-like peptide 1 levels in type 2 diabetes mellitus
  891. SGLT2–inhibitors in type-2 diabetes: The remaining questions!
  892. gem‐Dimethyl‐bearing C‐Glucosides as Sodium‐glucose Co‐transporter 2 (SGLT2) inhibitors
  893. 247-OR: real-world effectiveness of SGLT2 inhibitors vs. GLP-1 receptor agonists in patients with and without cardiovascular disease
  894. Are SGLT2 inhibitors joining the mainstream therapy for diabetes type 2?
  895. Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors and Stroke―Reply―
  896. SGLT2 inhibitors and ketoacidosis: pathophysiology and management
  897. 156-OR: Risk-Benefit of SGLT2 inhibitors (SGLT2i) vs. GLP-1 Receptor Agonists (GLP-1RA) in Routine Care of Older Adults
  898. SGLT2 inhibitors and euglycemic ketoacidosis
  899. Should we be combining GLP-1 receptor agonists and SGLT2 inhibitors in treating diabetes?
  900. SGLT2 inhibitors: cardiovascular benefits beyond glycemic control
  901. Molecular modeling studies of thiophenyl C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents
  902. SGLT2 inhibitors: a new therapeutic class for the treatment of type 2 diabetes mellitus
  903. Cardiovascular benefit of SGLT2 inhibitors in the therapeutics of diabetes mellitus: A close look beyond the horizon
  904. The role of SGLT2 inhibitors in type 2 diabetes
  905. Recognizing low endogenous insulin production as a precipitating factor of DKA in type-2 diabetic patients taking SGLT2 inhibitors: a case report
  906. Utility of SGLT2 inhibitors in patients with chronic heart failure with diabetes mellitus
  907. … Renal Threshold for Glucose Reabsorption in Type 1 Diabetes Mellitus (T1DM) May Explain the Smaller Contribution of SGLT2 inhibitors to the Improvement …
  908. Effects of SGLT2 inhibitors on Insulin Secretion and Insulin Resistance—Results from a Cross-Sectional Study
  909. Comparative Cardiovascular Effectiveness of SGLT2 inhibitors vs. Liraglutide in Routine Care
  910. Lower urinary tract symptoms (LUTS) in males with type 2 diabetes recently treated with SGLT2 inhibitors—overlooked and overwhelming? A retrospective case series
  911. Correction to: SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease
  912. P317 A novel role of SGLT2 inhibitors to increase circulating proangiogenic progenitor cells in patients with type 2 diabetes and cardiovascular disease: A sub-study …
  913. SGLT2 inhibitors reduce major adverse cardiovascular events in type 2 diabetic patients: a meta-analysis of randomized controlled trials
  914. Cardiac Energy Metabolism and the Role of SGLT2 inhibitors in Heart Failure
  915. SGLT2 inhibitors
  916. SGLT2 inhibitors compared with sitagliptin as add-on therapy to metformin in type 2 diabetes: a systematic review and meta-analysis
  917. Erratum. SGLT2 inhibitors in Combination Therapy: From Mechanisms to Clinical Considerations in Type 2 Diabetes Management. Diabetes Care 2018; 41: 1543 …
  918. DIABETIC COMPLICATIONS ASSOCIATED WITH SGLT2 AND DPP4 inhibitors: A REAL WORLD APPROACH
  919. Sodium glucose co-transporter 2 (SGLT2) inhibitors in type 2 diabetes: a literature review of approved products
  920. 1227-P: GlycoMark 1, 5-Anhydrocluitol values in patients taking SGLT2 inhibitors
  921. Role of sodium-glucose cotransporter 2 (SGLT2) inhibitors
  922. … and Ferrannini. Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 inhibitors. Diabetes Care 2015; 38: 1638 …
  923. Exploration of SAR regarding glucose moiety in novel C-aryl glucoside inhibitors of SGLT2
  924. Comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose cotransporter-2 inhibitors: SGLT2 inhibitors in the real world
  925. Therapeutic Potential of SGLT2 inhibitors in Treating Type 2 Diabetes Mellitus
  926. Fournier’s gangrene and sodium-glucose co-transporter 2 (SGLT2) inhibitors: Our experience
  927. SGLT2 inhibitors suppress alpha-adrenergic tone and morning elevation of plasma glucose levels
  928. Sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors from Sophora flavescens.
  929. Complementarity between randomised controlled trials and observational registries: the example of cardiovascular prevention with SGLT2 inhibitors
  930. Insight into the interaction mechanism of human SGLT2 with its inhibitors: 3D-QSAR studies, homology modeling, and molecular docking and molecular dynamics …
  931. Sodium Glucose Co-transporter Type 2 (SGLT2) inhibitors in CKD
  932. Euglycemic ketoacidosis: a complication of SGLT2 inhibitors
  933. SGLT2 inhibitors
  934. 2343-PUB: reduction of HbA1c after SGLT2 inhibitors correlate with change in plasma osmolarity but not with elevation of hematocrit in Japanese patients with type 2 …
  935. 1, 2, 4-Triazinylmethylphenyl glucoside as novel C-aryl glucoside SGLT2 inhibitors
  936. NON-CARDIAL EFFECTS OF SGLT2 inhibitors (REVIEW)
  937. The Elevation of Hematocrit after Administration of SGLT2 inhibitors Does Not Correlate with Plasma Osmolarity in Japanese Subjects with Type 2 Diabetes
  938. A Significance of Sodium-Glucose Cotransporter 1 (SGLT1) Inhibition by SGLT2 inhibitors
  939. SGLT2 inhibitors
  940. The Benefits of SGLT2 inhibitors in Cardiovascular Prevention, Glycemic Control and Weight Loss, in the Treatment of Diabetes
  941. Spiroketal Phthalane C-Glycosides: Synthesis of Papulacandins and SGLT2 inhibitors
  942. SUN-181 case report: rare complication of SGLT2 inhibitors can occur only 10 days after starting the medication
  943. SGLT2 inhibitors cost effective versus sulfonylureas in T2DM
  944. Comment on” comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in …
  945. P272 Additional use of SGLT2 inhibitors in the treatment of acute decompensated heart failure may prevent acute kidney injury
  946. FP499 PHARMACODYNAMIC REASON WHY THE DOSE OF SGLT2 inhibitors SHOULD NOT BE REDUCED IN PATIENTS WITH GFR LESS THAN 45 ML/MIN
  947. Os 32-05 Effects of SGLT2 inhibitors on circadian rhythm of blood pressure in rats
  948. How to use SGLT2 inhibitors safely
  949. … and Ferrannini. Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 inhibitors. Diabetes Care 2015; 38: 1638 …
  950. Annals On Call-SGLT2 inhibitors: The Good, the Bad, and the Ugly
  951. 2275-PUB: Relationship between the Effect of SGLT2 inhibitors and Dietary Intake in Japanese Patients with Type 2 Diabetes
  952. Exploration of novel C-glucoside formation and application for SGLT2 inhibitors-Discovery of canagliflozin as a SGL T2 inhibitor
  953. What Are The Benefits In The Association Of SGLT2 inhibitors And Other Drugs?
  954. Leaving the Glucocentric View: Can SGLT2 inhibitors Halt CVD in Patients With Type 2 Diabetes?
  955. Mechanisms and efficacy of SGLT2 inhibitors
  956. Efficiency and safety of SGLT2 inhibitors
  957. Promise, peril, and possible new treatment options incurred by sodium glucose co-transporter 2 (SGLT2) inhibitors: A precise review up to 2018
  958. Using SGLT2 inhibitors in Special Populations
  959. The SGLT2 inhibitors-a review: original
  960. A Review on Efficacy and Safety of SGLT2 inhibitors as Add-on Therapy with Metformin
  961. RENOPROTECTIVE EFFECTS OF SGLT2 inhibitors
  962. Sodium-glucose cotransporter 2 (SGLT2) inhibitors and stroke
  963. Effects of SGLT2 inhibitors in type 2 diabetes, comparing women to men
  964. SGLT2 inhibitors for Treating Diabetes
  965. GLYCEMIC OUTCOMES OF SGLT2 inhibitors IN OVERWEIGHT OR OBESE TYPE 2 DIABETES PATIENTS
  966. House of Carbs: the path to euglycemic DKA in patients with Diabetes on SGLT2 inhibitors
  967. In Silico Design Of Compounds As SGLT2 inhibitors
  968. The combination of GLP-1 analogs and SGLT2 inhibitors: new perspectives?
  969. Combination therapy with once weekly GLP 1 receptor agonist dulaglutide and SGLT2 inhibitors in Asian Indians with type 2 diabetes
  970. SGLT2–inhibitors and cardiovascular outcomes: inferences for clinical practice
  971. The Role of SGLT2 inhibitors in Clinical Practice
  972. SGLT2 inhibitors in Diabetes mellitus
  973. A NOVEL ROLE OF SGLT2 inhibitors TO INCREASE CIRCULATING PROANGIOGENIC PROGENITOR CELLS IN PATIENTS WITH TYPE 2 DIABETES AND …
  974. Safety of sodium-glucose cotransporter 2 inhibitors (SGLT2-I) during the month of Ramadan in Muslim patients with type 2 diabetes
  975. CLINCIAL EXPERIENCE WITH THE USE OF SODIUM GLUCOSE TRANSPORTERS SGLT2 inhibitors IN AN ENDOCRIONOLOGY OUTPATIENT CLINIC IN …
  976. THE ROLE OF SGLT2 inhibitors IN TYPE 2 DIABETES
  977. SAT-298 EFFECT OF SGLT2 inhibitors ON CARDIOVASCULAR, RENAL AND SAFETY OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS …
  978. Living with Type 2 Diabetes: Patient Commentary in Response to the Paper ‘SGLT2 inhibitors in Type 2 Diabetes Management: Key Evidence and …
  979. SGLT2 inhibitors: Now The Bad News
  980. The Use of SGLT2 inhibitors in Elderly Patients with Type 2 Diabetes Mellitus
  981. SGLT2 inhibitors for type 2 diabetes: Clinical considerations
  982. … Weight Reduction and Suppression of Cardiovascular Events in Recent Clinical Trials of DPP4 inhibitors, GLP-1 Receptor Agonists, and SGLT2 inhibitors
  983. Bitter sweet: Fournier’s Gangrene and SGLT2 inhibitors
  984. Erratum to: Sodium-glucose cotransporter 2 (SGLT2) inhibitors and cardiovascular disease: A systematic review
  985. Erratum to: sodium glucose co-transporter-2 (SGLT2) inhibitors: a review of their basic and clinical pharmacology
  986. TO STUDY THE SAFETY AND EFFICACY OF SGLT2 inhibitors AND OTHER ORAL HYPOGLYCAEMIC AGENTS WITH INSULIN IN UNCONTROLLED TYPE …
  987. MON-170 OUTCOMES OF SGLT2 inhibitors USE IN DIABETIC RENAL TRANSPLANT PATIENTS-SINGLE CENTER EXPERIENCE
  988. Cardiovascular safety of SGLT2 inhibitors
  989. A New Weapon in the Fight Against Diabetes: SGLT2 inhibitors
  990. SGLT2 inhibitors in T2D and associated comorbidities-differentiating within the class: correspondence
  991. … of Sodium-Glucose Cotransporter-2 (SGLT2) inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) inhibitors: A …
  992. COMPARISON OF EFFECTIVENESS OF SGLT2 inhibitors IN THE INDIAN MULTI ETHINIC TYPE 2 DIABETES PATIENTS-REAL WORLD EXPERIENCE
  993. SAT-LB013 The Effect of Select GLP1 Agonists and SGLT2 inhibitors on the Unfolded Protein Response in Primary Human Coronary Artery Endothelial Cells
  994. Novel natural and synthetic inhibitors of solute carriers SGLT1 and SGLT2
  995. Erratum to: practical approach to initiating SGLT2 inhibitors in type 2 diabetes
  996. Synthetic Studies towards Carbocyclic Analogues of SGLT2 inhibitors
  997. Discovery of natural SGLT2–inhibitors for Type 2 Diabetes–Possible Way to Reduce Side Effects
  998. A Medical Literature Review on Canagli?? ozin and Dapagli?? ozin and the Role of SGLT2 inhibitors in Diabetic Management
  999. SGLT2 inhibitors–IS THE PARADIGM IN TYPE 2 DIABETES MELLITUS MANAGEMENT CHANGING?
  1000. SGLT2 inhibitors and Ketoacidosis: Cause for Concern?
  1001. Frequently asked questions: SGLT2 inhibitors–a novel approach to managing hyperglycaemia
  1002. SGLT2 inhibitors: providing cardiovascular protection in type 2 diabetes?
  1003. Efficacy and safety of combination therapy with SGLT2 and DPP4 inhibitors in the treatment of type 2 diabetes: A systematic review and meta-analysis
  1004. SGLT2–inhibitors in the Management of Type 2 Diabetes
  1005. Glucose Lowering Effect of SGLT2 inhibitors: A Review of Clinical Studies
  1006. www. OpenCME. org/course/where-do-SGLT2–inhibitors-fit-spectrum-of-treatment-of-t2dm
  1007. Evaluation of Comparative Efficacy and Pleiotrophy of the Available Three SGLT2 inhibitors in Type 2 DM Subjects
  1008. “The Proof is in the Pudding”: Do SGLT2 inhibitors Cause Diabetic Ketoacidosis?
  1009. APPLICATION OF THE MINIMAL MODEL IN SUBJECTS TREATED WITH SGLT2 inhibitors
  1010. Relation Between HbA1c Level and Effectiveness of SGLT2 inhibitors in Diabetic Patients With Acute Decompensated Heart Failure
  1011. Predictors of response to SGLT2–inhibitors and DPP4-inhibitors: a MASTERMIND stratified medicine study
  1012. Efficacy of SGLT2 inhibitors as the Fifth Drug in the Management of Type 2 Diabetes Mellitus in Asian Indians not Controlled with at least 4 Oral Antidiabetic Drugs.
  1013. SGLT2 inhibitors: A Novel Therapy for Type 2 Diabetes Mellitus
  1014. Survey of Patient Comprehension of Medication Instructions for SGLT2 inhibitors
  1015. Meta-analysis of SGLT2 inhibitors and stroke risk in type 2 diabetic patients
  1016. The Renoprotective Effects of SGLT2 inhibitors versus Placebo in Patients with Type 2 Diabetes with or
  1017. SGLT2 inhibitors–new oral hypoglycemic drugs inhibitory SGLT2–nowe doustne leki przeciwcukrzycowe
  1018. Effects of SGLT2 inhibitors in the treatment of a population with type 2 diabetes mellitus
  1019. MHRA drug safety update: risk of Fournier’s gangrene with SGLT2 inhibitors for diabetes
  1020. The metabolic effects of SGLT2 inhibitors-Does the increase in ketone bodies protect the heart?
  1021. Maximizing Patient Safety with Newly Approved Therapies: Focus on SGLT2 inhibitors
  1022. FP408 NOVEL MOLECULAR MECHANISMS IN THE RENOPROTECTIVE EFFECT OF SGLT2 inhibitors VIA MITIGATION OF TUBULAR HYPOXIA AND PROTEIN …
  1023. 163-LB: Impact of SGLT2 inhibitors on Liver Function Test in Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Systemic Review and Meta-analysis
  1024. 2347-PUB: Relationship between Aging and Effects of SGLT2 inhibitors on Glucose and Lipid Metabolisms and Hepatic Function in Japanese Patients with Type 2 …
  1025. Letter to the Editor: Comment on “SGLT2 inhibitors may predispose to ketoacidosis” by Taylor SI, et al
  1026. SGLT2 inhibitors as adjunct therapy to insulin in type 1 diabetes: Meta analysis
  1027. 1962-P: Comparison of the Effects of Three SGLT2 inhibitors on Metabolic Parameters and Insulin Sensitivity in a Nondiabetic Rat Model of Metabolic Syndrome
  1028. The Role of SGLT2 inhibitors and DPP4 inhibitors in Preventing Diabetic Nephropathy
  1029. 1217-P: The Kidney Effects of the SGLT2 inhibitors on the Japanese Type 2 Diabetes Mellitus Patients with Chronic Kidney Disease
  1030. Renal SGLT2 inhibitors, new agents for the management of type 2 diabetes
  1031. 2350-PUB: Renoprotective Effects of SGLT2 inhibitors in Japanese Real-World Clinical Practice
  1032. Effect of SGLT2 inhibitors on glucagon secretion in pancreatic alpha cells
  1033. SUN-155 Clinical Experience of SGLT2 inhibitors in a Hispanic Population: Should We Consider Its Use as Add-On Treatment?
  1034. Euglycemic diabetic ketoacidosis in type 2-diabetes mellitus treated with SGLT2 inhibitors-a report on two cases
  1035. An Overview On Aryl C-glycosides As SGLT2 inhibitors With Antidiabetic Potential.
  1036. Evaluating Drug Cost per Response with SGLT2 inhibitors in Patients with Type 2 Diabetes Mellitus
  1037. Efficacy and Usefulness of SGLT2 inhibitors in Niddm Patients on the Backdrop of Metformin and Sulphonyl Urea
  1038. Improved preparation of C-aryl glucoside SGLT2 inhibitors
  1039. Prevalence of psychiatric comorbidities in diabetic patients who are candidates for therapy with SGLT2 inhibitors: clinical and metabolic characteristics
  1040. 25-LB: SGLT2 inhibitors Are Renoprotective via Mitigation of Tubular Hypoxia and Protein O-GlcNAcylation
  1041. An audit of SGLT2–inhibitors in the management of type 2 diabetes in Sligo University Hospital Ireland: metabolic and haemodynamic outcomes
  1042. ASSESSMENT OF SGLT2 inhibitors ON KIDNEY MORPHOLOGY AND ALBUMIN EXCRETION IN RATS WITH EXPERIMENTAL DIABETES MELLITUS TYPE 1.
  1043. 2340-PUB: Success of Online CME at Improving the Clinical Knowledge and Confidence in Using SGLT1/SGLT2 inhibitors in T1D Management
  1044. Dose-ranging effects of SGLT2 inhibitors in patients with type 2 diabetes: a systematic review and meta-analysis
  1045. 2354-PUB: Estimating Improvement of TGF Mechanism from Changes of Urinary Glucose and Sodium Excretion by SGLT2 inhibitors
  1046. Synthesis and biological evaluation of benzocyclobutane-C-glycosides as potent and orally active SGLT1/SGLT2 dual inhibitors
  1047. Impact of SGLT2 inhibitors (SGLT2i) on Cardiovascular (CV) Risk and Estimated Glomerular Filtration Rate (eGFR) in the EXSCEL Placebo Group
  1048. FP451 SIGNIFICANCE OF RENAL AUTONOMIC NERVES FOR WEIGHT-REDUCTION BY SGLT2 inhibitors
  1049. Meet the SGLT2 inhibitors: these new type 2 diabetes medications block glucose reabsorption by the kidneys
  1050. THE EMERGING ROLE OF SGLT2 inhibitors IN THE TREATMENT OF TYPE 2 DIABETES FOCUS ON EMPAGLIFLOZIN
  1051. OR22-1 Liraglutide as Add-on to SGLT2 inhibitors in Patients with Inadequately Controlled Type 2 Diabetes (LIRA-ADD2SGLT2i): A 26-Week, Randomized, Double …
  1052. Cardiorenal protection with SGLT2 inhibitors (gliflozins): from EMPA-REG OUTCOME to CANVAS
  1053. 2363-PUB: The efficacy of low vs. high FDA-approved SGLT2 inhibitor dose compared with DPP-4 inhibitors: a meta-analysis
  1054. Effects Of GLP-1 Analogues, DPP-4 inhibitors And SGLT2 inhibitors On The Renal System
  1055. Persistence to Treatment with DPP-4 inhibitors, SGLT2 inhibitors, and GLP-1-RAs Compared with Insulin after Failure with First Antidiabetic Drug in T2DM Patients
  1056. Comparative Cardiovascular Efficacy of SGLT2 inhibitors, DPP-4 inhibitors, and GLP-1 Agonists—A Network Meta-analysis
  1057. Comparative Effectiveness of SGLT2 inhibitors vs. Sitagliptin Add-on Therapy to Metformin inType-2 Diabetes
  1058. Disparities in the prescribing of DPP-4 inhibitors, SGLT2 inhibitors, and GLP-1 analogues in UK primary care
  1059. Cover Feature: Fluorine‐Directed Glycosylation Enables the Stereocontrolled Synthesis of Selective SGLT2 inhibitors for Type II Diabetes (Chem. Eur. J. 12/2018)
  1060. A survey of various adjuvant treatments used against type 1 diabetes, focusing on SGLT2 inhibitors
  1061. 12-month effects of incretins versus SGLT2–inhibitors on cognitive performance and metabolic profile. A randomized clinical trial in the elderly with Type-2 …
  1062. SGLT2 inhibitors Increase Bone Strength by Increasing Procollagen Type 1 Amino-Terminal Propeptide in Patients with Type 2 Diabetes
  1063. Combination therapy of SGLT2 inhibitors with incretin-based therapies for the treatment of type 2 diabetes mellitus: Effects and mechanisms of action
  1064. Rates of myocardial infarction and stroke in patients initiated on SGLT2–inhibitors versus other glucose-lowering agents in real-world clinical practice: results …
  1065. Control of Blood Glucose with Sodium Glucose Co-transporter 2 (SGLT2) inhibitors Among Patients with Type 2 Diabetes Mellitus
  1066. … in type 2 diabetes: harnessing individual-level trial data alongside routine care records to identify predictors of response to SGLT2 inhibitors and DPP4 inhibitors
  1067. Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors Drug Class Review
  1068. The Positive Effect of the Combination of GLP-1 Analogues and SGLT2 inhibitors on Obese Patients with Noninsulin-Treated DM2
  1069. … Glucose Co-Transporter 2 (SGLT2) inhibitors and Fracture Risk in Patients with Type 2 Diabetes Mellitus: A Meta-Analysis Short running title: SGLT2 inhibitors …
  1070. Type 2 Diabetes, SGLT2 inhibitors, and Glucose Secretion
  1071. Sodium-Glucose Co-Transporter-2 (SGLT2) inhibitors: Comparing Trial and Real World Use (Study Protocol)
  1072. The efficacy and safety of Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis
  1073. National prevalence of heart failure in type 2 diabetes patients derived from the National eHealth System and their access to treatment with SGLT2 inhibitors or GLP-1 …
  1074. Quality of methodological reporting of randomized clinical trials of sodium-glucose cotransporter-2 (SGLT2) inhibitors
  1075. Class Update: Sodium-glucose Cotransporter 2 (SGLT2) inhibitors
  1076. 2300-PUB: The Efficacy and Safety of Combinations of SGLT2 inhibitors and GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes: A Systematic Review and …
  1077. Health Expenditure Comparison of Diabetic Patients on Sodium-Glucose Co-Transporter 2 (SGLT2) inhibitors Vs Dipeptidyl Peptidase-4 (DPP4) inhibitors
  1078. Can Glucagon Like Peptide 1 (GLP1) Agonists or Sodium-Glucose Co-Transporter 2 (SGLT2) inhibitors Ameliorate Non-Alcoholic Steatohepatitis in People with or …
  1079. [PP. 05.19] EFFECTS OF SGLT2 inhibitors ON BLOOD PRESSURE, BAPWV, CAROTID ARTERIAL IMT AND ELASTIC MODULUS IN TYPE 2 DIABETIC …
  1080. Erratum to: Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors and Cardiovascular Disease: A Systematic
  1081. SYSTEMATIC REVIEW OF SODIUM GLUCOSE CO-TRANSPORTER 2 (SGLT2) inhibitors IN THE TREATMENT FOR PATIENTS WITH DIABETES …
  1082. COMPARATIVE EFFICACY OF 3 SGLT2 inhibitors AS THE FIFTH DRUG IN THE MANAGEMENT OF TYPE 2 DM IN ASIAN INDIANS NOT CONTROLLED WITH …
  1083. Sodium Glucose Co transporter 2 (SGLT2) inhibitors: A New Sword for the Treatment of Type 2 Diabetes Mellitus
  1084. A Five Featured Pharmacophore Model for the Sodium-Dependent Glucose Co-Transporter 2 (SGLT2) inhibitors
  1085. … of autonomous aldosterone secretion in patients with type 2 Diabetes Mellitus and arterial hypertension. The effect of SGLT2 inhibitors on renin-angiotensin …
  1086. SY 10-3 SGLT2 inhibitors AS POTENTIAL ANTIHYPERTENSIVE AND RENOPROTECTIVE AGENTS
  1087. P2521 Cardiovascular outcomes associated with SGLT2 vs DPP4 inhibitors in type 2 diabetic patients with and without established cardiovascular diseases: a …
  1088. SY 10-2 THE ROLE OF SGLT2 inhibitors IN THE MANAGEMENT OF T2DM
  1089. PS 11-73 BLOOD PRESSURE AND BODY WEIGHT LOWERING EFFECTS OF SODIUM-GLUCOSE CO-TRANSPORT 2 (SGLT2) inhibitors.
  1090. Lower Risk of CV Events and Death Associated with Initiation of SGLT2 vs. DPP-4 inhibitors—Analysis from the CVD-REAL 2 Study
  1091. The difference between SGLT2 and DPP-4 inhibitors on glucose fluctuation in patients with type 2 diabetes
  1092. Systematic Review of SGLT2 Receptor inhibitors in dual or triple therapy in type 2 diabetes
  1093. The position of new antidiabetics in clinical practice: SGLT2 vs DPP4 inhibitors
  1094. SGLT2 versus DPP4 inhibitors for Type 2 Diabetes: A Meta-analysis
  1095. Empagliflozin-the new representative of SGLT2 transporter inhibitors for the treatment of patients with diabetes 2 type
  1096. Audit on sodium glucose cotransporter-2 inhibitors (SGLT2) at Nottingham University Hospitals
  1097. Non-severe hypoglycemia risk difference between sulfonylurea and sodium-glucose cotransporter-2 inhibitors (SGLT2-I) as an add-on to metformin in …
  1098. Extraglycemic effects of SGLT2 inhibitors: a review of the evidence
  1099. Effects of SGLT2 inhibitors on kidney and cardiovascular function
  1100. SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control
  1101. SGLT2–inhibitors; more than just glycosuria and diuresis
  1102. Class effects of SGLT2 inhibitors on cardiorenal outcomes
  1103. Optimising the benefits of SGLT2 inhibitors for type 1 diabetes
  1104. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis
  1105. SGLT2 inhibitors may offer benefit beyond diabetes
  1106. Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study
  1107. Renal effects of SGLT2 inhibitors: an update
  1108. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials
  1109. Organ protection by SGLT2 inhibitors: role of metabolic energy and water conservation
  1110. Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors
  1111. SGLT2 inhibitors play a salutary role in heart failure via modulation of the mitochondrial function
  1112. SGLT2 inhibitors: a focus on cardiac benefits and potential mechanisms
  1113. Diabetic ketoacidosis with SGLT2 inhibitors
  1114. Renoprotection with SGLT2 inhibitors in type 2 diabetes over a spectrum of cardiovascular and renal risk
  1115. Renal protection: a leading mechanism for cardiovascular benefit in patients treated with SGLT2 inhibitors
  1116. SGLT2 inhibitors and kidney outcomes in patients with chronic kidney disease
  1117. What have we learned about renal protection from the cardiovascular outcome trials and observational analyses with SGLT2 inhibitors?
  1118. Recommendations on the proper use of SGLT2 inhibitors
  1119. Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta‐analysis
  1120. SGLT2 inhibitors for non-diabetic kidney disease: drugs to treat CKD that also improve glycaemia
  1121. SGLT2 inhibitors: the star in the treatment of type 2 diabetes?
  1122. Basic and clinical pharmaco-therapeutics of SGLT2 inhibitors: a contemporary update
  1123. Different effects of SGLT2 inhibitors according to the presence and types of heart failure in type 2 diabetic patients
  1124. The association between SGLT2 inhibitors and new-onset arrhythmias: a nationwide population-based longitudinal cohort study
  1125. SGLT2 inhibitors and atrial fibrillation in type 2 diabetes: a systematic review with meta-analysis of 16 randomized controlled trials
  1126. An exhaustive perspective on structural insights of SGLT2 inhibitors: A novel class of antidiabetic agent
  1127. SGLT2 inhibitors, an accomplished development in field of medicinal chemistry: An extensive review
  1128. Outcomes of SGLT2 inhibitors use in diabetic renal transplant patients
  1129. Molecular mechanisms by which SGLT2 inhibitors can induce insulin sensitivity in diabetic milieu: a mechanistic review
  1130. SGLT2 inhibitors produce cardiorenal benefits by promoting adaptive cellular reprogramming to induce a state of fasting mimicry: a paradigm shift in understanding …
  1131. Trends in clinical characteristics and prescribing preferences for SGLT2 inhibitors and GLP-1 receptor agonists, 2013–2018
  1132. Significance of SGLT2 inhibitors: lessons from renal clinical outcomes in patients with type 2 diabetes and basic researches
  1133. The effects of SGLT2 inhibitors on cardiovascular and renal outcomes in diabetic patients: a systematic review and meta-analysis
  1134. Use of SGLT2 inhibitors in cardiovascular diseases: why, when and how?
  1135. SGLT2 inhibitors and lower limb complications: an updated meta‐analysis
  1136. Minireview: are SGLT2 inhibitors heart savers in diabetes?
  1137. SGLT2 inhibitors–a potential treatment for Alport syndrome
  1138. SGLT2 inhibitors in people with and without T2DM
  1139. Use of SGLT2 inhibitors during Ramadan: an expert panel statement
  1140. Regression of left ventricular hypertrophy with SGLT2 inhibitors
  1141. Early initiation of SGLT2 inhibitors is important, irrespective of ejection fraction: SOLOIST‐WHF in perspective
  1142. CCS/CHFS heart failure guidelines: clinical trial update on functional mitral regurgitation, SGLT2 inhibitors, ARNI in HFpEF, and tafamidis in amyloidosis
  1143. Proximal tubule mTORC1 is a central player in the pathophysiology of diabetic nephropathy and its correction by SGLT2 inhibitors
  1144. SGLT2 inhibitors in Diabetic Kidney Disease
  1145. SGLT2 inhibitors for treatment of refractory hypomagnesemia: a case report of 3 patients
  1146. SGLT2 inhibitors: slowing of chronic kidney disease progression in type 2 diabetes
  1147. Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational …
  1148. SGLT2 inhibitors reduce infarct size in reperfused ischemic heart and improve cardiac function during ischemic episodes in preclinical models
  1149. SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications
  1150. SGLT2 inhibitors and cardiovascular and renal outcomes: a meta-analysis and trial sequential analysis
  1151. Are the cardiorenal benefits of SGLT2 inhibitors due to inhibition of the sympathetic nervous system?
  1152. SGLT2 inhibitors, GLP-1 agonists, and DPP-4 inhibitors in diabetes and microvascular complications: a review
  1153. Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation
  1154. Are SGLT2 inhibitors safe and effective in advanced diabetic kidney disease?
  1155. Mechanisms leading to differential hypoxia-inducible factor signaling in the diabetic kidney: modulation by SGLT2 inhibitors and hypoxia mimetics
  1156. SGLT2 inhibitors, sodium and off-target effects: An overview
  1157. We can finally stop worrying about SGLT2 inhibitors and acute kidney injury
  1158. Do SGLT2 inhibitors increase the risk of amputation? Make haste slowly
  1159. SGLT2 inhibitors: diabetic kidney disease and beyond
  1160. Are the benefits of SGLT2 inhibitors in heart failure and a reduced ejection fraction influenced by background therapy? Expectations and realities of a new …
  1161. The role of renal hypoxia in the pathogenesis of diabetic kidney disease: a promising target for newer renoprotective agents including SGLT2 inhibitors?
  1162. Does metformin interfere with the cardiovascular benefits of SGLT2 inhibitors? Questions about its role as the cornerstone of diabetes treatment
  1163. Diabetic Agents, From Metformin to SGLT2 inhibitors and GLP1 Receptor Agonists: JACC Focus Seminar
  1164. The Effects of SGLT2 inhibitors on Lipid Metabolism
  1165. The expanding role of SGLT2 inhibitors beyond glucose-lowering to cardiorenal protection
  1166. SGLT2 inhibitors: Emerging Roles in the Protection Against Cardiovascular and Kidney Disease Among Diabetic Patients
  1167. Combination therapy with SGLT2 inhibitors for diabetic kidney disease
  1168. Critical examination of mechanisms underlying the reduction in heart failure events with SGLT2 inhibitors: identification of a molecular link between their actions to …
  1169. Evolving understanding of cardiovascular protection by SGLT2 inhibitors: focus on renal protection, myocardial effects, uric acid, and magnesium balance
  1170. Comparative effectiveness of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of kidney outcomes: emulation of a target trial …
  1171. Optimising the Heart Failure Treatment Pathway: The Role of SGLT2 inhibitors
  1172. Use of SGLT2 inhibitors and occurrence of noninfectious respiratory disorders: a meta-analysis of large randomized trials of SGLT2 inhibitors
  1173. Evidence against an important role of plasma insulin and glucagon concentrations in the increase in EGP caused by SGLT2 inhibitors
  1174. Efficacy and safety profile of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease
  1175. SGLT2 inhibitors in liver patients
  1176. The Role of SGLT2 inhibitors in Vascular Aging
  1177. Focused updates: SGLT2 inhibitors in patients with heart failure and/or chronic kidney disease
  1178. Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review
  1179. Role of ketogenic starvation sensors in mediating the renal protective effects of SGLT2 inhibitors in type 2 diabetes
  1180. Decision algorithm for prescribing SGLT2 inhibitors and GLP-1 receptor agonists for diabetic kidney disease
  1181. SGLT2 inhibitors and the autonomic nervous system in diabetes: a promising challenge to better understand multiple target improvement
  1182. SGLT2 inhibitors as add-on therapy to metformin for people with type 2 diabetes: a review of placebo-controlled trials in asian versus non-asian patients
  1183. The efficacy and safety of combinations of SGLT2 inhibitors and GLP-1 receptor agonists in the treatment of type 2 diabetes or obese adults: a systematic review and …
  1184. Effects and safety of SGLT2 inhibitors compared to placebo in patients with heart failure: A systematic review and meta-analysis
  1185. Pharmacokinetic/pharmacodynamic properties and clinical use of SGLT2 inhibitors in non-Asian and Asian patients with type 2 diabetes and chronic kidney disease
  1186. Control of 24-hour blood pressure with SGLT2 inhibitors to prevent cardiovascular disease
  1187. Effects of SGLT2 inhibitors on eGFR in type 2 diabetic patients—the role of antidiabetic and antihypertensive medications
  1188. Kidney and cardiovascular protection with SGLT2 inhibitors: lessons from cardiovascular outcome trials and CREDENCE
  1189. Reduction in HbA1c with SGLT2 inhibitors vs. DPP-4 inhibitors as add-ons to metformin monotherapy according to baseline HbA1c: A systematic review of …
  1190. SGLT2 inhibitors, What the Emergency Physician Needs to Know: A Narrative Review
  1191. SGLT2 inhibitors and GLP1 agonists administered without metformin compared to other glucose‐lowering drugs in patients with type 2 diabetes mellitus to prevent …
  1192. Compelling evidence for SGLT2 inhibitors and GLP-1 receptor agonists as first-line therapy in patients with diabetes at very high/high cardiovascular risk
  1193. The sweet spot: heart failure prevention with SGLT2 inhibitors
  1194. SGLT2 inhibitors and Other Novel Therapeutics in the Management of Diabetic Kidney Disease
  1195. Biomarker evidence for distal tubular damage but cortical sparing in hospitalized diabetic patients with acute kidney injury (AKI) while on SGLT2 inhibitors
  1196. SGLT2 inhibitors for heart failure with reduced ejection fraction: a real EMPEROR?
  1197. Relative efficacy of sacubitril-valsartan, vericiguat, and SGLT2 inhibitors in heart failure with reduced ejection fraction: a systematic review and network meta-analysis
  1198. SGLT2 inhibitors and the Risk of Hospitalization for Fournier’s Gangrene: A Nested Case–Control Study
  1199. Use of SGLT2 inhibitors in Older Adults: Scientific Evidence and Practical Aspects
  1200. SGLT2 inhibitors: a novel player in the treatment and prevention of diabetic cardiomyopathy
  1201. Exploring sodium glucose co-transporter-2 (SGLT2) inhibitors for organ protection in COVID-19
  1202. SGLT2 inhibitors and renal complications in type 1 diabetes
  1203. Effect of SGLT2 inhibitors on stroke and atrial fibrillation in diabetic kidney disease: results from the CREDENCE trial and meta-analysis
  1204. Impact of sodium glucose cotransporter 2 (SGLT2) inhibitors on atherosclerosis: from pharmacology to pre-clinical and clinical therapeutics
  1205. Emergence of SGLT2 inhibitors as Powerful Antioxidants in Human Diseases
  1206. Making a case for the combined use of SGLT2 inhibitors and GLP1 receptor agonists for cardiorenal protection
  1207. Why Choose Between SGLT2 inhibitors and GLP1-RA When You Can Use Both? The Time to Act Is Now
  1208. SGLT2 inhibitors for prevention of cardiorenal events in people with type 2 diabetes without cardiorenal disease: A meta-analysis of large randomized trials and cohort …
  1209. Association between sodium-glucose cotransporter 2 (SGLT2) inhibitors and lower extremity amputation: a systematic review and meta-analysis
  1210. Recommendations on the proper use of SGLT2 inhibitors
  1211. Subtype‐dependent reporting of stroke with SGLT2 inhibitors: implications from a Japanese pharmacovigilance study
  1212. SGLT2 inhibitors for type 2 diabetes mellitus in adults: an overview of forty‐six systematic reviews
  1213. Effect of SGLT2–inhibitors on Epicardial Adipose Tissue: A Meta-Analysis
  1214. Meta‐analysis on the efficacy and safety of SGLT2 inhibitors and incretin based agents combination therapy vs. SGLT2i alone or add‐on to metformin in type 2 …
  1215. Association between combined treatment with SGLT2 inhibitors and metformin for type 2 diabetes mellitus on fracture risk: a meta-analysis of randomized controlled …
  1216. A literature review and meta-analysis of safety profiles of SGLT2 inhibitors in Japanese patients with diabetes mellitus
  1217. SGLT2 inhibitors and bladder cancer: Analysis of cases reported in the European pharmacovigilance database
  1218. The pharmacological profile of SGLT2 inhibitors: Focus on mechanistic aspects and pharmacogenomics
  1219. SGLT2 inhibitors and thiazide enhance excretion of DEHP toxic metabolites in subjects with type 2 diabetes: A randomized clinical trial
  1220. The efficacy and safety of SGLT2 inhibitors combined with ACEI/ARBs in the treatment of type 2 diabetes mellitus: A meta-analysis of randomized controlled studies
  1221. Acute renal failure, ketoacidosis, and urogenital tract infections with SGLT2 inhibitors: signal detection using a Japanese spontaneous reporting database
  1222. Impact of SGLT2 inhibitors on Heart Failure: From Pathophysiology to Clinical Effects
  1223. Effects of SGLT2 inhibitors on stroke and its subtypes in patients with type 2 diabetes: a systematic review and meta-analysis
  1224. SCORED and SOLOIST: the next scores for SGLT2 inhibitors
  1225. The Multiple Effects of SGLT2 inhibitors Suggest Potential Benefit in COVID-19 Patients
  1226. Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: A meta-analysis of 34 randomized …
  1227. SGLT2 inhibitors and the Clinical Implications of Associated Weight Loss in Type 2 Diabetes: A Narrative Review
  1228. Effects of SGLT2 inhibitors on cardiovascular and renal outcomes in type 2 diabetes: A meta-analysis with trial sequential analysis
  1229. SGLT2 inhibitors in patients with type 2 diabetes with non-alcoholic fatty liver diseases: an umbrella review of systematic reviews
  1230. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a …
  1231. Sodium glucose cotransporter 2 (SGLT2) inhibitors across the spectrum of hypertension
  1232. Klotho: A possible mechanism of action of SGLT2 inhibitors preventing episodes of acute kidney injury and cardiorenal complications of diabetes
  1233. Effects of SGLT2 inhibitors as an add-on therapy to metformin on electrocardiographic indices of ventricular repolarization
  1234. Unexpected Pleiotropic Effects of SGLT2 inhibitors: Pearls and Pitfalls of This Novel Antidiabetic Class
  1235. Predisposing factors for the development of diabetic ketoacidosis with lower than anticipated glucose levels in type 2 diabetes patients on SGLT2–inhibitors: a review
  1236. The Role of SGLT2 inhibitors in Heart Failure: A Systematic Review and Meta-Analysis
  1237. SGLT2 inhibitors, hemodynamics, and kidney protection
  1238. Real-world risk of hypoglycemia-related hospitalization in Japanese patients with type 2 diabetes using SGLT2 inhibitors: a nationwide cohort study
  1239. Are SGLT2 inhibitors New Hypertension Drugs?
  1240. Reductions in albuminuria with SGLT2 inhibitors: a marker for improved renal outcomes in patients without diabetes?
  1241. SGLT2 inhibitors across the Spectrum of Severity of CKD
  1242. Do reductions in risk of cardiorenal events with SGLT2 inhibitors in type 2 diabetes vary with baseline characteristics? A meta-analysis
  1243. SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure: A systematic review and meta-analysis
  1244. SGLT2 inhibitors for genetic and acquired insulin resistance: Considerations for clinical use
  1245. Systematic review and meta-analysis: SGLT2 inhibitors, blood pressure and cardiovascular outcomes
  1246. Safety of four SGLT2 inhibitors in three chronic diseases: A meta-analysis of large randomized trials of SGLT2 inhibitors
  1247. Syntheses of SGLT2 inhibitors by Ni-and Pd-Catalyzed Fukuyama Coupling Reactions
  1248. Endogenous Fructose Metabolism Could Explain the Warburg Effect and the Protection of SGLT2 inhibitors in Chronic Kidney Disease
  1249. Safety and Efficacy of SGLT2 inhibitors: A Multiple-Treatment Meta-Analysis of Clinical Decision Indicators
  1250. Biocomputational Prediction Approach Targeting FimH by natural SGLT2 inhibitors: A Possible Way to Overcome the Uropathogenic Effect of SGLT2 inhibitor Drugs
  1251. Blood pressure control in type 2 diabetes mellitus with arterial hypertension. The important ancillary role of SGLT2–inhibitors and glp1-receptor agonists
  1252. Risk of cardiovascular outcomes in patients with type 2 diabetes after addition of SGLT2 inhibitors versus sulfonylureas to baseline GLP-1RA therapy
  1253. SGLT2 inhibitors and risk of diabetic ketoacidosis in patients with type 2 diabetes: systematic review and meta-analysis of randomized controlled trials.
  1254. SGLT2 inhibitors break the vicious circle between heart failure and insulin resistance: targeting energy metabolism
  1255. SGLT2 inhibitors: expanding their Empire beyond diabetes
  1256. Organ protection beyond glycaemic control with SGLT2 inhibitors
  1257. SGLT2 inhibitors and the Mechanisms Involved in Weight Loss
  1258. Acute kidney injury events in patients with type 2 diabetes using SGLT2 inhibitors versus other glucose-lowering drugs: a retrospective cohort study
  1259. Renal outcomes of SGLT2 inhibitors and GLP1 agonists in clinical practice
  1260. SGLT2 inhibitors: the story continues to unfold
  1261. SGLT2 inhibitors increase risk for diabetic ketoacidosis in type 2 diabetes
  1262. Sympatholytic Mechanisms for the Beneficial Cardiovascular Effects of SGLT2 inhibitors: A Research Hypothesis for Dapagliflozin’s Effects in the Adrenal Gland
  1263. Effects of Sodium/Glucose Cotransporter 2 (SGLT2) inhibitors on Cardiovascular and Metabolic Outcomes in Patients Without Diabetes Mellitus: A Systematic Review …
  1264. Are current SGLT2 inhibitors efficacious treatment options for Type 1 diabetes?
  1265. Are the protective effects of SGLT2 inhibitors a” class-effect” or are there differences between agents?
  1266. SGLT2 inhibitors in Resistant Hypertension: A Sweet Solution
  1267. Beware ketoacidosis with SGLT2 inhibitors in latent autoimmune diabetes of the adult
  1268. Impact of SGLT2 inhibitors in comparison with DPP4 inhibitors on ascites and death in veterans with cirrhosis on metformin
  1269. SGLT2 inhibitors reduce all-cause mortality
  1270. Impact of SGLT2 inhibitors on cardiovascular outcomes in patients with heart failure with reduced ejection fraction
  1271. The influence of long‐term administration of SGLT2 inhibitors on blood pressure at the office and at home in patients with type 2 diabetes mellitus and chronic kidney …
  1272. SGLT2 inhibitors: renal outcomes according to baseline albuminuria
  1273. SGLT2 inhibitors: The Dawn of a New Era in Cardio-Metabolic Therapeutics
  1274. GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: A systematic review and meta-analysis
  1275. Cardioprotection by SGLT2 inhibitors—Does It All Come Down to Na+?
  1276. Communicating emerging risks of SGLT2 inhibitors—timeliness and transparency of medicine regulators
  1277. The sodium-glucose cotransporter-2 (SGLT2) inhibitors synergize with nitric oxide and prostacyclin to reduce human platelet activation
  1278. Renal haemodynamic and protective effects of renoactive drugs in type 2 diabetes: Interaction with SGLT2 inhibitors
  1279. Prescribing of SGLT2 inhibitors in primary care: a qualitative study of General Practitioners and Endocrinologists
  1280. Effectiveness and Safety of SGLT2 inhibitors in Clinical Routine Treatment of Patients with Diabetes Mellitus Type 2
  1281. Meta-Analysis on the Safety and Cardiorenal Efficacy of SGLT2 inhibitors in Patients Without T2DM
  1282. When and for Whom Should We Use SGLT2 inhibitors in HFrEF?
  1283. A real-world comparison of cardiovascular, medical and costs outcomes in new users of SGLT2 inhibitors versus GLP-1 agonists
  1284. SGLT2 inhibitors in cardiovascular medicine
  1285. Can CMR Elucidate the Cardiovascular Benefit of SGLT2 inhibitors?
  1286. Diabetes, heart failure and beyond: elucidating the cardioprotective mechanisms of sodium glucose cotransporter 2 (SGLT2) inhibitors
  1287. Diabetic ketoacidosis in patients treated with SGLT2 inhibitors: experience at a tertiary hospital
  1288. Cardiovascular benefits of SGLT2 inhibitors in patients with heart failure: a meta-analysis of small and large randomized controlled trials
  1289. SGLT2 inhibitors as Calorie Restriction Mimetics: Insights on Longevity Pathways and Age-Related Diseases
  1290. Meta‐analysis of the effects of four factors on the efficacy of SGLT2 inhibitors in patients with HFrEF
  1291. … “SGLT2 inhibitors and cardiovascular and renal outcomes: a meta-analysis and trial sequential analysis” Cardiac, renal protection with SGLT2 inhibitors is evident but …
  1292. Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A …
  1293. SGLT2 inhibitors and lower limb complications: the diuretic-induced hypovolemia hypothesis
  1294. GLP-1 Receptor agonists and SGLT2 inhibitors for the treatment of type 2 diabetes: new insights and opportunities for cardiovascular protection
  1295. Identifying Risk Factors for Diabetic Ketoacidosis Associated with SGLT2 inhibitors: a Nationwide Cohort Study in the USA
  1296. Efficacy and cardiovascular safety of SGLT2 inhibitors.
  1297. Neural tone and cardio-renal outcomes in patients with type 2 diabetes mellitus: a review of the literature with a focus on SGLT2 inhibitors
  1298. SGLT2 inhibitors: Who Should Prescribe Them for Patients With Heart Failure?
  1299. Effect of SGLT2 inhibitors on Type 2 Diabetes Mellitus With Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials
  1300. SGLT2 inhibitors and cardiovascular outcomes: do they differ or there is a class effect? New insights from the EMPA-REG OUTCOME trial and the CVD-REAL study
  1301. Letter to the Editor regarding the article “SGLT2 inhibitors and cardiovascular and renal outcomes: a meta‑analysis and trial sequential analysis”
  1302. Glucosuria Interferes With Measurement of Effective Renal Plasma Flow Using para-Aminohippuric Acid, With a Focus on SGLT2 inhibitors
  1303. SGLT2 inhibitors for improving hepatic fibrosis and steatosis in non-alcoholic fatty liver disease complicated with type 2 diabetes mellitus: a systematic review
  1304. The Pleiotropic Effects of SGLT2 inhibitors: Remodeling the Treatment of Heart Failure
  1305. Bittersweet: infective complications of drug-induced glycosuria in patients with diabetes mellitus on SGLT2–inhibitors: two case reports
  1306. Efficacy and safety of SGLT2 inhibitors in type 1 diabetes after the introduction of an off-label use protocol for clinical practice
  1307. Global Mechanisms Proposed for Cardioprotective Effects of SGLT2 inhibitors
  1308. SGLT2 inhibitors and the cardiac Na+/H+ exchanger-1: the plot thickens
  1309. SGLT2 inhibitors as potentially helpful drugs in PI3K inhibitor-induced diabetes: a case report
  1310. SGLT2 inhibitors: a narrative review of efficacy and safety
  1311. SGLT2 inhibitors and the risk of diabetic ketoacidosis: A systematic review and meta-analysis
  1312. SGLT2 inhibitors and euglycemic diabetic ketoacidosis
  1313. How do SGLT2 (sodium-glucose cotransporter 2) inhibitors and GLP-1 (glucagon-like peptide-1) receptor agonists reduce cardiovascular outcomes? Completed and …
  1314. Do four SGLT2 inhibitors lead to different cardiorenal benefits in type 2 diabetes, in chronic heart failure, and in chronic kidney disease?
  1315. Reno-protective potential of sodium glucose cotransporter-2 (SGLT2) inhibitors: Summary evidence from clinical and real-world data
  1316. Are the antidiabetic SGLT2 inhibitors a cardiovascular treatment?
  1317. Efficacy of Continuing SGLT2 inhibitors on Outcomes in Patients with Acute Decompensated Heart Failure
  1318. Can treatment response to SGLT2–inhibitors in syndrome of inappropriate antidiuresis be predicted by Copeptin, natriuretic peptides and inflammatory markers?
  1319. Sodium-Glucose Co-Transporter 2 (SGLT2) inhibitors: Are They All the Same? A Narrative Review of Cardiovascular Outcome Trials
  1320. SGLT2 inhibitors and the risk of diabetic ketoacidosis among adults with Type 2 Diabetes: A systematic review and meta-analysis
  1321. Effects of SGLT2 inhibitors on cardiovascular, renal, and major safety outcomes in heart failure: A meta-analysis of randomized controlled trials
  1322. Efficacy/safety balance of DPP-4 inhibitors versus SGLT2 inhibitors in elderly patients with type 2 diabetes
  1323. Real-life prescribing of SGLT2 inhibitors: How to handle other medications, including glucose-lowering drugs and diuretics
  1324. Meta-analysis of the effect of SGLT2 inhibitors on hepatic fibrosis in patients with T2DM complicated with NAFLD.
  1325. Euglycemic diabetic ketoacidosis with COVID-19 infection in patients with type 2 diabetes taking SGLT2 inhibitors
  1326. Marked hypertriglyceridemia in a patient with type 2 diabetes receiving SGLT2 inhibitors
  1327. Could metformin modulate cardiovascular outcomes differently with DPP-4 inhibitors compared with SGLT2 inhibitors?
  1328. The potential roles of osmotic and non-osmotic sodium handling in mediating effects of SGLT2 inhibitors on heart failure
  1329. SGLT2 inhibitors and Kidney and Cardiac Outcomes According to Estimated GFR and Albuminuria Levels: A Meta-analysis of Randomized Controlled Trials
  1330. SGLT2 inhibitors: What role do they play in heart failure with reduced ejection fraction?
  1331. In type 2 diabetes, SGLT2 inhibitors were linked to diabetic ketoacidosis vs. DPP-4 inhibitors
  1332. Clinical Influence of Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors for Cardiovascular and Renal Points of View
  1333. SGLT2 inhibitors Induced Hypercalcemia: A Case Series and Literature Review.
  1334. The Rationale and Evidence for SGLT2 inhibitors as a Treatment for Nondiabetic Glomerular Disease
  1335. Optimizing use of SGLT2 inhibitors and other evidence-based therapies to improve outcomes in patients with type 2 diabetes and chronic kidney disease: An …
  1336. Do SGLT2 inhibitors Act Only Through a Functional Tubuloglomerular Feedback Induced by the Increased Outflow of Sodium?
  1337. 324-OR: Global Use of SGLT2 inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes: Results from DISCOVER
  1338. Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
  1339. Comparing the clinical outcomes across different sodium/glucose cotransporter 2 (SGLT2) inhibitors in heart failure patients: a systematic review and network meta …
  1340. The effect of SGLT2 inhibitors on silent myocardial ischemia
  1341. Cost-effectiveness of intensification with SGLT2 inhibitors for type 2 diabetes.
  1342. Cardiovascular Safety of SGLT2 inhibitors Compared to DPP4 inhibitors and Sulfonylureas as the Second-Line of Therapy in T2DM Using Large, Real-World …
  1343. Relationship Between HbA1c Level and Effectiveness of SGLT2 inhibitors in Decompensated Heart Failure Patients with Type 2 Diabetes Mellitus
  1344. MO647 RENOPROTECTIVE EFFECT OF SGLT2 inhibitors AFTER FIVE YEARS OF TREATMENT: AN OBSERVATIONAL STUDY
  1345. The EMPEROR-Reduced trial: SGLT2 inhibitors for heart failure get more support
  1346. Under-prescription of SGLT2 inhibitors in patients with diabetes and cardiovascular disease in the United States
  1347. SGLT2 inhibitors and sleep apnea; how helpful are the medications: A meta-analysis
  1348. Interaction Between Non-Insulin Glucose-Lowering Medication and Exercise in Type 2 Diabetes Mellitus–New Findings on SGLT2 inhibitors
  1349. EMPEROR-Reduced supports the use of SGLT2 inhibitors for the treatment of patients with heart failure and reduced ejection fraction: Comment on the EMPEROR …
  1350. Antihypertensive and renal mechanisms of SGLT2 (sodium-glucose linked transporter 2) inhibitors
  1351. Does Combination Therapy With SGLT2 inhibitors and Renin–Angiotensin System Blockers Lead to Greater Reduction in Cardiorenal Events Among Patients …
  1352. Euglycemic DKA Associated With SGLT2 inhibitors
  1353. SGLT2 inhibitors: the Gift that Keeps on Giving
  1354. … of type 2 diabetes mellitus with the development of new-onset atrial fibrillation in patients with non-ischemic dilated cardiomyopathy: impact of SGLT2 inhibitors
  1355. Integrated computational approach on sodium-glucose co-transporter 2 (SGLT2) inhibitors for the development of novel antidiabetic agents
  1356. Empagliflozin-Associated Pancreatitis: A Consideration for SGLT2 inhibitors
  1357. SGLT2 inhibitors in patients with cirrhosis and diabetes mellitus: A tertiary center cohort study and insights about a potential therapeutic target for portal hypertension
  1358. Diabetes medications with cardiovascular protection as we enter a new decade: can SGLT2 inhibitors, long-acting GLP-1 receptor agonists, pioglitazone and …
  1359. In type 2 diabetes, SGLT2 inhibitors reduce all-cause, but not cardiovascular, mortality vs. GLP-1 RAs
  1360. Beyond the myocardium? SGLT2 inhibitors target peripheral components of reduced oxygen flux in the diabetic patient with heart failure with preserved ejection …
  1361. Do SGLT2 inhibitors prevent preclinical diabetic retinopathy? A Prospective Pilot Optical Coherence Tomography Angiography Study
  1362. The Effects of SGLT2 inhibitors on Lipid Metabolism. Metabolites 2021, 11, 87
  1363. Biochemical Interaction Analysis of natural SGLT2 inhibitors with Alzheimer Targets: A Computational Approach.
  1364. To Heart “Fail” or Not? The Expanding Role of SGLT2 inhibitors
  1365. Synthesis of Benzyl C‐Analogues of Dapagliflozin as Potential SGLT2 inhibitors
  1366. Risk of DKA with SGLT2 inhibitors
  1367. SGLT2 inhibitors: the Gift that Keeps on Giving
  1368. Patient and clinical characteristics of heart failure patients concomitantly prescribed SGLT2 inhibitors and sacubitril/valsartan, a database cohort study using the …
  1369. Comparing cardiovascular benefits between GLP-1 receptor agonists and SGLT2 inhibitors as an add-on to metformin among patients with type 2 diabetes: A …
  1370. Effects of SGLT2 inhibitors as an Add-on Therapy to Metformin on Electrocardiographic Indices of Ventricular Repolarization
  1371. Metabolic outcomes in patients with diabetes mellitus administered SGLT2 inhibitors immediately before emergency or elective surgery: single centre experience and …
  1372. Comprehensive evaluation of cardiovascular efficacy and safety outcomes of SGLT2 inhibitors in high risk patients of cardiovascular disease: systematic …
  1373. Efficacy and Safety of SGLT2 inhibitors in Diabetic Kidney Transplant Patients: Review of the Current Literature
  1374. Clinical and Economic Rationale for the Early use of SGLT2 inhibitors in Patients with Type 2 Diabetes
  1375. SGLT2 inhibitors in type 2 diabetic patients with renal function impairment slows the annual renal function decline, in a real clinical practice.
  1376. … effects of sirtuin-1 and its downstream effectors: potential role in mediating the heart failure benefits of SGLT2 (sodium-glucose cotransporter 2) inhibitors
  1377. Efficacy of DPP-4 inhibitors and SGLT2 inhibitors compared to sulphonylureas in adult patients with diabetes with low c-peptide levels with or without anti-GAD65 …
  1378. Payment Coverage and Health Economics of SGLT2 inhibitors
  1379. A mechanistic rationale for the investigation of SGLT2 inhibitors in HFpEF-Letter regarding the article’Baseline Characteristics of Patients with Heart Failure with …
  1380. Do SGLT2 inhibitors Improve Cardio-Renal Outcomes in Patients With Type II Diabetes Mellitus: A Systematic Review
  1381. A paradigm shift in preventing diabetic heart failure? A review of SGLT2 inhibitors.
  1382. The association between SGLT2 inhibitors and new-onset arrhythmias: a nationwide population-based longitudinal cohort study
  1383. SGLT2 inhibitors and kidneys: mechanisms and main effects in diabetes mellitus patients
  1384. P1010 EFFECTS OF SGLT2 inhibitors ON DIABETIC NEPHROPATHY: PODOCYTURIA ON FOCUS
  1385. … causes an increase in endog-enous glucose production (EGP). However, the mechanisms are unclear. We studied the effect of SGLT2 inhibitors on EGP in …
  1386. Commentary: SGLT2 inhibitors reduce mortality and heart failure in patients with type 2 diabetes mellitus—is metabolic reprogramming the mechanism for these …
  1387. Optimizing Utilization of SGLT2 inhibitors in an Outpatient LVAD Population
  1388. Postoperative extremity gangrene in a patient with type 2 diabetes taking SGLT2 inhibitors: A case report
  1389. Euglycemic Diabetic Ketoacidosis Caused by SGLT2 inhibitors and a Ketogenic Diet: A Case Series and Review of Literature
  1390. Uric acid is a biomarker of oxidative stress in the failing heart: lessons learned from trials with allopurinol and SGLT2 inhibitors
  1391. SGLT2 inhibitors: A new era for our patients
  1392. BS16 The role of parasympathetic nervous system in the infarct-limiting effect of SGLT2 inhibitors
  1393. Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors & Kidney Transplantation: What Are We Waiting For?
  1394. MO654 REAL LIFE EXPERIENCE AFTER 20 MONTHS USING SGLT2 inhibitors
  1395. Sodium-Glucose Cotransporter (SGLT2) inhibitors: A new Era in renovascular protection
  1396. SGLT2 inhibitors: only beneficial?
  1397. Comparative effects of sodium glucose cotransporter 2 (SGLT2) inhibitors and dipeptidyl peptidase-4 (DPP4) inhibitors on new-onset atrial fibrillation and stroke …
  1398. SGLT2 inhibitors and kidney outcomes in the real world
  1399. Fournier’s Gangrene and Diabetic Ketoacidosis Associated with Sodium Glucose Co-Transporter 2 (SGLT2) inhibitors: Life-Threatening Complications
  1400. Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation
  1401. Real-World Clinical Experience with SGLT2 inhibitors: Use of Special Screening Tool for Type 2 Diabetes Patients to Avoid Serious Adverse Events: A Single-Centre …
  1402. Recent Developments in Sodium-Glucose Co-Transporter 2 (SGLT2) inhibitors as a Valuable Tool in the Treatment of Type 2 Diabetes Mellitus
  1403. How to fill the GAPS-I in secondary prevention: application of a strategy based on GLP1 analogues, antithrombotic agents, PCSK9 inhibitors, SGLT2 inhibitors and …
  1404. Practical considerations in the use of SGLT2 inhibitors in cardiovascular diseases
  1405. P1038 NEPHROPROTECTIVE EFFECT OF SGLT2 inhibitors DURING FIRST YEAR OF TREATMENT
  1406. SGLT2 inhibitors improve plasma atherogenic biomarkers in patients with type 2 diabetes: a real world retrospective observational study.
  1407. 1097-P: Disposition Index Is a Predictor of Urinary Glucose Excretion in Subjects Treated with SGLT2 inhibitors
  1408. Prolonged Glucosuria With Sodium-Glucose Cotransporter-2 (SGLT2) inhibitors: A Case Report and Review of Literature
  1409. SGLT2 inhibitors: A revolution in therapeutics of a Major Non-Communicable Disease
  1410. THE ROLE OF SGLT2 inhibitors BEYOND GLUCOSE-LOWERING TO CARDIO-RENAL PROTECTION
  1411. Extending the use of SGLT2 inhibitors from diabetic to non-diabetic kidney disease
  1412. Therapeutic interventions of novel SGLT2 inhibitors against metabolic disorders: inserting the association into perspectives.
  1413. Tandem positive action of SGLT2 inhibitors and ARNI in patients with heart failure
  1414. SGLT2 inhibitors and nephroprotection in diabetic kidney disease: From mechanisms of action to the latest evidence in the literature
  1415. P1047 URICOSURIA AND URINARY GLUCOSE EXCRETION ON DIABETIC KIDNEY DISEASE (DKD) PATIENTES TREATED WITH SGLT2 inhibitors
  1416. SGLT2 inhibitors: focus on kidneys and nephroprotection
  1417. Possible Mechanisms of Action of SGLT2 inhibitors in Heart Failure
  1418. 1145-P: SGLT2 inhibitors Improve Day-to-Day Glucose Variability in Patients with Type 1 Diabetes
  1419. 36-OR: Comparative effectiveness of SGLT2 inhibitors vs. GLP-1 agonists
  1420. Role of SGLT2 inhibitors in Heart Failure
  1421. Evolving physicians’ perceptions and practices regarding use of SGLT2 inhibitors for type 2 diabetes during Ramadan fasting
  1422. SGLT2 inhibitors and the Risk of Major Adverse Cardiovascular Events: A Multi-database Study Using a Prevalent New-User Design
  1423. When and how to use SGLT2 inhibitors in patients with HFrEF or chronic kidney disease.
  1424. 35-OR: Risk of Cardiovascular Outcomes in Diabetes Patients following the Addition of SGLT2 inhibitors vs. Sulfonylureas to Baseline GLP-1RA Therapy
  1425. SGLT2 inhibitors in diabetic and non-diabetic nephropathies
  1426. SGLT2 inhibitors: A Noval Therapuetic Agent in the Treatment of Diabetic Kidney Disease
  1427. Weight loss differences seen between glucagon-like-peptide-1 (GLP-1) receptor agonists and sodium glucose cotransporter-2 (SGLT2) inhibitors for treatment of type …
  1428. Cardiovascular Outcome in Patients Treated With SGLT2 inhibitors for Heart Failure: A Meta-Analysis
  1429. RE: Should we stick to SGLT2 inhibitors?
  1430. Cardio-Renal Benefits of SGLT2 inhibitors in Heart Failure with Reduced Ejection Fraction: Mechanisms and Clinical Evidence.
  1431. Why Are SGLT2 inhibitors Nephroprotective? Mechanisms of Action And Possible Benefits A Review
  1432. The position of SGLT2 inhibitors in current medicine.
  1433. P1009 RENAL OUTCOMES IN DIABETIC KIDNEY PATIENTS TREATED WITH GLP1 AGONIST RECEPTORS VS SGLT2 inhibitors
  1434. SGLT2 inhibitors, new option to prevent or treat heart failure
  1435. Cost Analysis of SGLT2 inhibitors in patients with type 2 Diabetes in India
  1436. A Review of the Role of Type 2 Diabetes and SGLT2 inhibitors in Heart Failure with Preserved Ejection Fraction.
  1437. Improving Utilization of SGLT2 inhibitors in the Inpatient Setting
  1438. … -P: Effect of Raised Alanine Transaminase (ALT) Levels on HbA1c in the Association of British Clinical Diabetologists (ABCD) Nationwide Audits of SGLT2 inhibitors …
  1439. SGLT2 inhibitors and Heart Failure Outcomes
  1440. Mechanistic evaluation of the effect of SGLT2 inhibitors on delayed glucose absorption in patients with type 2 diabetes mellitus using a quantitative systems …
  1441. Effects of SGLT2 inhibitors on stroke in type 2 diabetes according to baseline kidney function
  1442. A Comprehensive Review on various HPLC based Analytical techniques used for the Estimation of SGLT2 inhibitors type of Antidiabetic drugs in various …
  1443. SGLT2 inhibitors, beyond glucose-lowering effect: impact on nephrology clinical practice
  1444. CLINICAL PRACTICE PATTERNS AND ATTITUDES ABOUT PRESCRIBING SGLT2 inhibitors AT A SINGLE-CENTER ACADEMIC SAFETY-NET HOSPITAL
  1445. 778-P: SGLT2 inhibitors, GLP-1 Receptor Agonists, and DPP-4 inhibitors and Risk of All-Cause Hospitalization
  1446. SGLT2 inhibitors in patients with chronic kidney disease: from clinical trials to guidelines and new prospects for clinical practice
  1447. SGLT2 inhibitors–No Longer Just for Those with Diabetes
  1448. Differential Cardiovascular and Renal Benefits of SGLT2 inhibitors and GLP1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus
  1449. AGE AND SEX-BASED DIFFERENCES IN CARDIOVASCULAR OUTCOMES OF SGLT2 inhibitors
  1450. Sodium-glucose co-transporter 2 (SGLT2) inhibitors
  1451. SGLT2 inhibitors-SOMETHING IN THE WATER, OR THE HEART OF THE MATTER?
  1452. Is the joint use of diuretics and SGLT2 inhibitors beneficial in diabetic kidney disease?
  1453. SGLT2 inhibitors and their association with balanoposthitis and Fournier’s gangrene.
  1454. EXPANDING THE ROLE OF SGLT2 inhibitors ACROSS THE DIABETIC SPECTRUM
  1455. SGLT2 inhibitors and all-cause mortality: a meta-analysis of randomized controlled trials.
  1456. Heart failure protection by SGLT2 inhibitors in patients with type 2 diabetes mellitus: evidence and possible mechanisms: A systematic review
  1457. Comparative effectiveness and safety of SGLT2 inhibitors versus metformin in patients with type-2 diabetes: An observational study using data from routine care.
  1458. 198 Primary care use of SGLT2 inhibitors in patients with type 2 diabetes mellitus and cardiovascular disease–are we missing a trick?
  1459. SGLT2 inhibitors DECREASE CARDIOVASCULAR MORTALITY OR HEART FAILURE HOSPITALIZATIONS IN HEART FAILURE SUBGROUPS: A SYSTEMATIC …
  1460. 101 Heart failure, diabetes and use of SGLT2 inhibitors–a missed opportunity
  1461. SGLT2 inhibitors and CKD in 2021
  1462. Reply to Comment: Is there any place for SGLT2–inhibitors in post-liver transplantation patients?
  1463. Why are SGLT2 inhibitors a good choice in the management of Type 2 Diabetes Mellitus?
  1464. Association of SGLT2 inhibitors with outcomes in Type 2 diabetes with reduced and preserved left ventricular ejection fraction-Analysis from the CVD-REAL 2 Study.
  1465. SGLT2 inhibitors in Patients with Diabetes and Cardiovascular Disease
  1466. Safety of SGLT2 inhibitors: A Pharmacovigilance Study From 2015 to 2020 Based on FDA Adverse Event Report System Database
  1467. Overview of Sodium-Glucose Co-transporter 2 (SGLT2) inhibitors for the Treatment of Non-diabetic Heart Failure Patients
  1468. SGLT2 inhibitors and diabetic nephropathy: sweet nothings
  1469. … Ali, Muhammad Umer Ahmed, Sundas, Muhammad Aslam Khan, Qalb Khan, Gul Muhammad Memon, Izhan Ali Khan. Role of SGLT2 inhibitors in Heart Failure
  1470. Correction to: Optimising the Benefits of SGLT2 inhibitors for Type 1 Diabetes
  1471. CARDIOLOGIST USE OF SGLT2 inhibitors AND GLP-1 RECEPTOR AGONISTS SINCE RELEASE OF FAVORABLE CARDIOVASCULAR OUTCOMES TRIALS: A …
  1472. Cardiovascular and renal protection with SGLT2 inhibitors: from EMPA-REG OUTCOME to VERTIS CV
  1473. SAFETY AND EFFICACY OF SGLT2 inhibitors POST ORTHOTOPIC HEART TRANSPLANTATION
  1474. Effect of Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors on Left Ventricular Remodelling and Longitudinal Strain: A Prospective Observational Study
  1475. SGLT2 inhibitors: Do we need other evidences?
  1476. In HFrEF Don’t Throw the Baby out with the Bathwater! SGLT2 inhibitors: Numbers Needed to Treat or Harm
  1477. 777-P: Efficacy of SGLT2 inhibitors and GLP1-Receptor Agonists in Asians with Type 2 Diabetes: A Systemic Review and Meta-analysis
  1478. SGLT2 inhibitors, GLP-1 Receptor Agonists, or Bariatric Surgery and Risks of All-Cause Mortality, Cardiovascular Diseases, End-Stage Renal Diseases, and Severe …
  1479. 681-P: Effect of 3-Month Therapy with SGLT2 inhibitors and GLP-1 Agonists on Ambulatory Blood Pressure in Patients with Type 2 Diabetes Mellitus
  1480. Prevention of cardiovascular disease and renal failure in type 2 diabetes: sodium-glucose cotransporter-2 (SGLT2) inhibitors
  1481. Effectiveness and safety of SGLT2 inhibitors compared to dipeptidyl peptidase (DPP)-4 inhibitors in older adults with type 2 diabetes: A nationwide population-based …
  1482. 081 Assessment of SGLT2 inhibitors use in Heart Failure Patients at a Tertiary Hospital
  1483. Lowering the Risk of Gout: Another Benefits from Use of SGLT2 inhibitors
  1484. SGLT2 inhibitors improved time in range without increasing hypoglycemia in Japanese patients with type 1 diabetes: A retrospective single-center pilot study
  1485. Evidences on SGLT2 inhibitors and NOACs and their relevance to the Bhutanese health system
  1486. A Comparison of the Effects of SGLT2 inhibitors in Heart Failure Patients with Diabetes Versus Non-diabetic Patients
  1487. 88-LB: Kidney and Metabolic Benefits by Adding GLP-1 Agonists and/or SGLT2 inhibitors on Metformin in Obese Type 2 Diabetes (T2DM) Patients: 24-Month Real …
  1488. Real-life clinical experience with GLP1 analogs and SGLT2 inhibitors in the treatment of diabetes type 2 and obesity
  1489. 402-P: Liraglutide Might Have Synergistic Renal Protection Effect with SGLT2 inhibitors in Rapidly Progressive Diabetic Kidney Disease
  1490. Cardiorenal outcomes and T2DM control in new users of SGLT2 inhibitors in combination therapy
  1491. Comparing impact of SGLT2 inhibitors and GLP-1 agonists on lipid profile among the patients with diabetes mellitus Type 2. Results of a prospective 18-week …
  1492. 779-P: Prescribing of SGLT2 inhibitors in Primary Care: A Qualitative Study of Primary Care Physicians and Endocrinologists
  1493. In a real-world population, SGLT2 inhibitors resulted in a significant but less than expected reduction in HbA1c, weight and systolic blood pressure at 12 months …
  1494. 172 Untold Story of SGLT2 inhibitors
  1495. Effects and Safety of SGLT2 inhibitors on Cardiovascular and Renal Outcomes in Patients with Chronic Kidney Disease: A Systematic Review and Meta-Analysis of …
  1496. THE INFLUENCE OF THE INTRODUCTION OF 3 NEW CLASSES OF DIABETES TYPE 2 MEDICATION (DPP-4 inhibitors, SGLT2 inhibitors AND GLP-1 …
  1497. 787-P: Individualized Estimated GFR Slope Analysis Is Needed to Preserve Renal Function by SGLT2 inhibitors in Patients with DKD
  1498. SGLT2 inhibitors ARE NOT ASSOCIATED WITH RISKS FOR AMPUTATION-A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED …
  1499. EFFECT OF SGLT2 inhibitors ON LIPID PARAMETERS: A META-ANALYSIS OF 30 RANDOMIZED CLINICAL TRIALS AND 10,246 PATIENTS
  1500. SGLT2 inhibitors for gout: Do these antihyperglycaemic agents reduce uric acid levels?
  1501. Use of sodium-glucose co-transporter-2-inhibitors (SGLT2-Is) and risk of lower limb amputation
  1502. Incidence of Heart Failure Hospital Admissions Among Type 2 Diabetes Mellitus Patients and the Potential Impact of SGLT2 inhibitors in Japan: A Population-based …
  1503. 1431-P: Risk of Venous Thromboembolism amongst Initiators of SGLT2 inhibitors Compared with Other Glucose-Lowering Agents
  1504. 987-P: Comparative Cardiovascular (CV) Effectiveness of SGLT2 inhibitors (SGLT2i) and GLP-1 Receptor Agonists (GLP-1 RA) in Patients with Type 2 Diabetes …
  1505. 1124-P: SGLT2 inhibitors as Adjuvant Therapy for Type 1 Diabetes: An Italian Center Experience
  1506. Clinical And Biochemical Outcomes Of Sodium-Glucose Co-Transporter-2 (SGLT2) inhibitors In Type 2 Diabetes Mellitus Patients
  1507. REVIEW OF EFFICACY AND SHORT TERM SAFETY OF SODIUM-GLUCOSE COTRANSPORTER 2 (SGLT2) inhibitors USE IN DIABETIC RENAL TRANSPLANT …
  1508. Barriers to initiating SGLT2 inhibitors in diabetic kidney disease: a real-world study
  1509. Potential Unrealized Mortality Benefit of GLP-1 Receptor Agonists and SGLT2 inhibitors: A Report from the Veterans Health Administration Clinical Assessment …
  1510. 2218-PUB: Initiation of SGLT2 inhibitors in Hospitalized Patients with CVD
  1511. PRETREATMENT WITH SGLT2 inhibitors AMELIORATES CONTRAST-INDUCED NEPHROPATHY
  1512. 1162-P: Coverage, Formulary Restrictions, and Average Retail Prices of SGLT2 inhibitors and GLP-1 Receptor Agonists across Medicare Part D Plans in 2019
  1513. 1200-P: Use of SGLT2 inhibitors in Hospitalized Patients in an Academic Center
  1514. 34-OR: SGLT2 inhibitors: A Comparison of Cardiovascular, Medical, and Cost Outcomes
  1515. 137-LB: Early Performance Under SGLT2 inhibitors in High-Risk Patients: EARLY PUSH Study: A Prospective Double-Blind Comparative Study
  1516. 812-P: The Role of Industry and NIH/Academia in the Clinical Development of GLP-1 Agonists and SGLT2 inhibitors
  1517. … Background between Patients with and without Increased Glucagon Secretion while on SGLT2 inhibitors: A Comparison of Canagliflozin and Other SGLT2 inhibitors
  1518. 1211-P: Real-World Use of SGLT2 inhibitors in a Large US Safety-Net Health System
  1519. 5PSQ-123 SGLT2 inhibitors in type 2 diabetes patients with non-alcoholic fatty liver diseases: an umbrella review of systematic reviews
  1520. 141-LB: The Reality of Diabetic Ketoacidosis in Patients with Type 2 Diabetes Using SGLT2 inhibitors Revealed by a Nationwide Claim-Based Database in Japan
  1521. Decrease of coronary heart disease risk with GLP1-receptor agonists or SGLT2 inhibitors therapy in patients with type 2 diabetes in primary cardiovascular prevention …
  1522. 1141-P: Effects of SGLT2 inhibitors on Nighttime Sympathetic Nerve Activity, Heart Rate, Blood Pressure Variability, and Glycemic Variability in Type 2 Diabetic …
  1523. Role of DPP-4 and SGLT2 inhibitors Connected to Alzheimer Disease in Type 2 Diabetes Mellitus
  1524. 1433-P: Protective Effect of GLP-1 Receptor Agonists (GLP-1 RA) and SGLT2 inhibitors (SGLT2i) against Adverse Cardiovascular (CV) Events in HIV and Type 2 …
  1525. 1115-P: Comparative Rate of Amputations among Type 2 Diabetes Patients Starting Different SGLT2 inhibitors
  1526. 676-P: Ideal Ketone Test Training among Type 1 Patients in Context of Risk Associated with SGLT2 inhibitors
  1527. SGLT2 inhibitors in CKD: Innovation after 20 years
  1528. … therapy: comparison between the two classes of drugs GLPR (glucagon-like peptide receptor) agonists and SGLT2 (sodium–glucose cotransporter 2) inhibitors
  1529. … των αναστολέων του συν-μεταφορέα νατρίου-γλυκόζης 2, Mechanisms of action and organ protection of sodium-glucose cotran-sporter inhibitors-2 (SGLT2)
  1530. Sodium-glucose cotransporter 2 inhibitors (SGLT2-I) ameliorate ascites and peripheral edema in patients with cirrhosis and diabetes.
  1531. Letter to the Editor: Sodium-glucose cotransporter 2 inhibitors (SGLT2-I) ameliorate ascites and peripheral edema in patients with cirrhosis and diabetes.
  1532. 5, 5-Difluoro-and 5-Fluoro-5-methyl-hexose-based C-Glucosides as potent and orally bioavailable SGLT1 and SGLT2 dual inhibitors
  1533. natural products with SGLT2 inhibitory activity: Possibilities of application for the treatment of diabetes
  1534. … of diabetes mellitus-imperative role of natural products against dipeptidyl peptidase-4, α-glucosidase and sodium-dependent glucose co-transporter 2 (SGLT2)
  1535. Investigation on the Anti-diabetic Effects of Selected natural Products/Chinese Herbs by Inhibiting the Activity of Sodium-glucose Cotransporter 2 (SGLT2)
  1536. From natural Product to New Diabetes Therapy: Phlorizin and the Discovery of SGLT2 inhibitor Clinical Candidates
  1537. SGLT2 inhibition—a novel strategy for diabetes treatment
  1538. SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects
  1539. Renal, metabolic and cardiovascular considerations of SGLT2 inhibition
  1540. SGLT2 inhibition and kidney protection
  1541. SGLT2 inhibition in the diabetic kidney—from mechanisms to clinical outcome
  1542. Nephroprotection by SGLT2 inhibition: back to the future?
  1543. SGLT2 inhibition for the prevention and treatment of diabetic kidney disease: a review
  1544. SGLT2 inhibition in the diabetic kidney–an update
  1545. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition
  1546. SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?
  1547. SGLT2 inhibition and COVID-19: The road not taken.
  1548. SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment
  1549. Effects of SGLT2 inhibition in human kidney proximal tubular cells—renoprotection in diabetic nephropathy?
  1550. Modeling oxygen consumption in the proximal tubule: effects of NHE and SGLT2 inhibition
  1551. SGLT2 inhibition and heart failure—current concepts
  1552. SGLT2 inhibition during the COVID-19 epidemic: Friend or foe?
  1553. SGLT2 inhibition mediates protection from diabetic kidney disease by promoting ketone body-induced mTORC1 inhibition
  1554. SGLT2 inhibition and glucagon secretion in humans
  1555. Determinants of the increase in ketone concentration during SGLT2 inhibition in NGT, IFG and T2DM patients
  1556. SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart
  1557. SGLT2 inhibition slows tumor growth in mice by reversing hyperinsulinemia
  1558. SGLT2 inhibition reprograms systemic metabolism via FGF21-dependent and-independent mechanisms
  1559. SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease
  1560. Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia
  1561. Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration
  1562. SGLT2 inhibition in a kidney with reduced nephron number: modeling and analysis of solute transport and metabolism
  1563. More CREDENCE for SGLT2 inhibition
  1564. Unmasking a sustained negative effect of SGLT2 inhibition on body fluid volume in the rat
  1565. SGLT2 inhibition: changing what fuels the heart
  1566. Paradoxical insights into whole body metabolic adaptations following SGLT2 inhibition
  1567. Renal and cardiovascular effects of SGLT2 inhibition in combination with loop diuretics in patients with type 2 diabetes and chronic heart failure: the RECEDE-CHF …
  1568. Unraveling reno-protective effects of SGLT2 inhibition in human proximal tubular cells
  1569. SGLT2 inhibition to address the unmet needs in diabetic nephropathy
  1570. The limited role of glucagon for ketogenesis during fasting or in response to SGLT2 inhibition
  1571. Cardiovascular and renal benefits of SGLT2 inhibition: insights from CANVAS
  1572. SGLT2 inhibition via dapagliflozin improves generalized vascular dysfunction and alters the gut microbiota in type 2 diabetic mice
  1573. Research into the effect Of SGLT2 inhibition on left ventricular remodelling in patients with heart failure and diabetes mellitus (REFORM) trial rationale and …
  1574. SGLT2 inhibition by empagliflozin promotes fat utilization and browning and attenuates inflammation and insulin resistance by polarizing M2 macrophages in …
  1575. Osmotic diuresis by SGLT2 inhibition stimulates vasopressin‐induced water reabsorption to maintain body fluid volume
  1576. SGLT2 protein expression is increased in human diabetic nephropathy: SGLT2 protein inhibition decreases renal lipid accumulation, inflammation, and the …
  1577. SGLT2 inhibition and renal urate excretion: role of luminal glucose, GLUT9, and URAT1
  1578. Glucagon levels during short-term SGLT2 inhibition are largely regulated by glucose changes in patients with type 2 diabetes
  1579. SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob/ob−/− mice
  1580. The role of glucagon in the acute therapeutic effects of SGLT2 inhibition
  1581. Perspective of SGLT2 inhibition in treatment of conditions connected to neuronal loss: Focus on Alzheimer’s Disease and ischemia-related brain injury
  1582. Cardiovascular benefits of SGLT2 inhibition in diabetes and chronic kidney diseases
  1583. Targeting the kidney and glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 …
  1584. SGLT2 inhibition reduces atherosclerosis by enhancing lipoprotein clearance in Ldlr−/− type 1 diabetic mice
  1585. Cardiac substrate utilization in heart failure: Where is the relevance of SGLT2 inhibition?
  1586. Increase in endogenous glucose production with SGLT2 inhibition is attenuated in individuals who underwent kidney transplantation and bilateral native …
  1587. Mechanistic effects of SGLT2 inhibition on blood pressure in diabetes
  1588. A reduced M1-like/M2-like ratio of macrophages in healthy adipose tissue expansion during SGLT2 inhibition
  1589. Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo-or euglycemic conditions in rats
  1590. Osmotic diuresis with SGLT2 inhibition: analysis of events related to volume reduction in dapagliflozin clinical trials
  1591. SGLT2 inhibition requires reconsideration of fundamental paradigms in chronic kidney disease,’diabetic nephropathy’, IgA nephropathy and podocytopathies with …
  1592. Concise and stereodivergent synthesis of carbasugars reveals unexpected structure-activity relationship (SAR) of SGLT2 inhibition
  1593. SGLT2 inhibition with empagliflozin increases circulating provascular progenitor cells in people with type 2 diabetes mellitus
  1594. SGLT2 inhibition and ketoacidosis–should we be concerned?
  1595. SGLT2 Inhibition does not affect myocardial fatty acid oxidation or uptake, but reduces myocardial glucose uptake and blood flow in individuals with type 2 diabetes: a …
  1596. SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: Report of a scientific workshop sponsored by the National Kidney Foundation
  1597. Combining SGLT2 inhibition with a thiazolidinedione additively attenuate the very early phase of diabetic nephropathy progression in type 2 diabetes mellitus
  1598. A variation on the theme: SGLT2 inhibition and glucagon secretion in human islets
  1599. Mechanism of increased LDL (low-density lipoprotein) and decreased triglycerides with SGLT2 (sodium-glucose cotransporter 2) inhibition
  1600. An exploration of the heterogeneity in effects of SGLT2 inhibition on cardiovascular and all-cause mortality in the EMPA-REG OUTCOME, CANVAS Program …
  1601. Increase in endogenous glucose production with SGLT2 inhibition is unchanged by renal denervation and correlates strongly with the increase in urinary glucose …
  1602. The effect of acute dual SGLT1/SGLT2 inhibition on incretin release and glucose metabolism after gastric bypass surgery
  1603. Predictors of the response of HbA1c and body weight after SGLT2 inhibition
  1604. Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes
  1605. SGLT2 Inhibition on Cardiac Mitochondrial Function: Searching for a Sweet Spot
  1606. Heal Thyself: SGLT2 Inhibition Limits Regenerative Cell Exhaustion and Heals Damaged Vessels
  1607. Sodium-glucose cotransporter 2 (SGLT2) inhibition in kidney transplant recipients with diabetes mellitus
  1608. SGLT2 inhibition: a new era in renoprotective medicine?
  1609. SGLT2 inhibition: A novel prospective strategy in treatment of diabetes mellitus
  1610. Hepatic gluconeogenic response to single and long-term SGLT2 inhibition in lean/obese male hepatic G6pc-reporter mice
  1611. Sodium glucose transporter 2 (SGLT2) inhibition and ketogenesis
  1612. Renal and Cardiovascular Effects of sodium–glucose cotransporter 2 (SGLT2) inhibition in combination with loop Diuretics in diabetic patients with Chronic …
  1613. … treatment effects on electrolyte and acid–base balance: secondary analysis of a clinical trial reaching glycemic equipoise: Tubular effects of SGLT2 inhibition in Type 2 …
  1614. SGLT2 inhibition reduces cellular senescence in the diabetic kidney by promoting ketone body‐induced NRF2 activation
  1615. SGLT2 inhibition with dapagliflozin: a novel approach for the management of type 2 diabetes
  1616. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion
  1617. Ertugliflozin (steglatro): a new option for SGLT2 inhibition
  1618. Rapid onset of diabetic ketoacidosis after SGLT2 inhibition in a patient with unrecognized acromegaly
  1619. SGLT2 inhibition increases serum copeptin in young adults with type 1 diabetes
  1620. SGLT2 inhibition by intraperitoneal dapagliflozin mitigates peritoneal fibrosis and ultrafiltration failure in a mouse model of chronic peritoneal exposure to high-glucose …
  1621. Inhibition of SGLT2: a novel strategy for treatment of type 2 diabetes mellitus
  1622. SGLT2 inhibition for cardiovascular diseases, chronic kidney disease and NAFLD
  1623. Systemic Actions of SGLT2 Inhibition on Chronic mTOR Activation as a Shared Pathogenic Mechanism between Alzheimer’s Disease and Diabetes
  1624. Effects of sodium-glucose co-transporter 2 (SGLT2) inhibition on renal function and albuminuria in patients with type 2 diabetes: a systematic review and meta …
  1625. SGLT2 inhibition may precipitate euglycemic DKA after bariatric surgery
  1626. SGLT2 Inhibition by Dapagliflozin Attenuates Diabetic Ketoacidosis in Mice with Type-1 Diabetes
  1627. SGLT2 inhibition and chronic kidney disease outcomes: in diabetes and beyond
  1628. The effect of sodium/glucose cotransporter 2 (SGLT2) inhibition on the urinary proteome
  1629. Pharmacodynamic model of sodium–glucose transporter 2 (SGLT2) inhibition: implications for quantitative translational pharmacology
  1630. Effect of sodium-glucose cotransporter 2 (SGLT2) inhibition on weight loss is partly mediated by liver-brain-adipose neurocircuitry
  1631. Comparison of mechanisms and transferability of outcomes of SGLT2 inhibition between type 1 and type 2 diabetes
  1632. The dawn of the four-drug era? SGLT2 inhibition in heart failure with reduced ejection fraction
  1633. Synthesis of novel N-glycoside derivatives via CuSCN-catalyzed reactions and their SGLT2 inhibition activities
  1634. Does SGLT1 Inhibition Add Benefit to SGLT2 Inhibition in Type 2 Diabetes Mellitus?
  1635. Does SGLT2 Inhibition Affect Sympathetic Nerve Activity in Type 2 Diabetes?
  1636. Renal effects of antisense-mediated inhibition of SGLT2
  1637. Model‐based evaluation of proximal sodium reabsorption through SGLT2 in health and diabetes and the effect of inhibition with canagliflozin
  1638. Research digest: SGLT2 inhibition in kidney and liver disease
  1639. Combined SGLT2 and DPP4 inhibition reduces the activation of the Nlrp3/ASC inflammasome and attenuates the development of diabetic nephropathy in mice with …
  1640. A potential diagnostic problem on the ICU: Euglycaemic diabetic Ketoacidosis associated with SGLT2 inhibition
  1641. SGLT2 is not expressed in pancreatic α-and β-cells, and its inhibition does not directly affect glucagon and insulin secretion in rodents and humans
  1642. Inhibition of SGLT2 alleviates diabetic nephropathy by suppressing high glucose‐induced oxidative stress in type 1 diabetic mice
  1643. SGLT2 inhibition does not reduce glucose absorption during experimental peritoneal dialysis
  1644. SGLT2-Inhibition reverts urinary peptide changes associated with severe COVID-19: an in-silico proof-of-principle of proteomics-based drug repurposing
  1645. Inhibition of the sodium–glucose co‐transporter SGLT2 by canagliflozin ameliorates diet‐induced obesity by increasing intra‐adipose sympathetic innervation
  1646. MO620 ANTIFIBROTIC EFFECTS OF SGLT2 INHIBITION IN THE KIDNEY AND PROXIMAL TUBULAR CELLS
  1647. SGLT2 inhibition: an effective therapeutic approach in the treatment of diabetes mellitus?
  1648. Softening the Stiff Heart: SGLT2 Inhibition and Diastolic Function
  1649. Paternal Obesity and SGLT2 Inhibition Alter Expression of Placental Regulatory Genes
  1650. Adaptive Response as a Potential Key Link between SGLT2 Inhibition and Renoprotection
  1651. SGLT1 does compensate for SGLT2 inhibition
  1652. What makes SGLT2 inhibition so effective in lowering blood glucose in diabetes?(689.5)
  1653. Empagliflozin and Protecting Microvascular Support of Heart Mechanics: SGLT2 Inhibition or More?
  1654. Commentary: Benefits of SGLT2 inhibition in heart failure: A bellwether for importance of other metabolic pathways
  1655. SGLT2 inhibition alleviated hyperglycemia, glucose intolerance, and dumping syndrome-like symptoms in a patient with glycogen storage disease type Ia: a …
  1656. … 2 (SGLT2) inhibition causes an increase in endog-enous glucose production (EGP). However, the mechanisms are unclear. We studied the effect of SGLT2 …
  1657. What Does SGLT2 Inhibition Add in Managing Hyponatremia Secondary to Syndrome of Inappropriate Antidiuresis (SIAD)?
  1658. Mechanisms of SGLT2 (Sodium-Glucose Transporter Type 2) Inhibition-Induced Relaxation in Arteries From Human Visceral Adipose Tissue
  1659. Sodium Glucose Co-Transporter2 (SGLT2) Inhibition for Refractory Hypomagnesemia in Monogenic Diabetes Type 5 (MODY 5)
  1660. Competitive inhibition of SGLT2 by tofogliflozin or phlorizin induces urinary glucose excretion through extending splay in cynomolgus monkeys
  1661. SGLT2-inhibition and Vascular Euphoria a Reconciliation of Vascular Health and Disease Homeostasis.
  1662. Inhibition of soluble epoxide hydrolase alleviates insulin resistance and hypertension via downregulation of SGLT2 in the mouse kidney
  1663. SO022 EVALUATION OF GLOMERULAR HEMODYNAMIC CHANGES BY SGLT2 INHIBITION IN TYPE 2 DIABETIC RATS USING IN VIVO IMAGING TECHNIQUES
  1664. … with insulin shows important effects on Zn2+-transporters in cardiomyocytes from insulin-resistant metabolic syndrome rats through inhibition of oxidative stress
  1665. P0984 SGLT2 INHIBITION PREVENTS RENAL FIBROSIS IN CYCLOSPORINE NEPHROPATHY
  1666. LB005 KIDNEY IMPLICATIONS OF THE INITIAL EGFR RESPONSE TO SGLT2 INHIBITION WITH EMPAGLIFLOZIN: THE ‘EGFR DIP’IN EMPA-REG OUTCOME
  1667. Metabolic and endocrine effects of SGLT2 inhibition
  1668. 150 SGLT2 inhibition in heart failure with a reduced ejection fraction: how many patients would benefit?
  1669. 396-P: SGLT2 Inhibition Suppresses Glucagon Response to Hypoglycemia in Male but Not Female Rats with Streptozotocin-Induced Type 1 Diabetes
  1670. Sodium glucose co-transporter 2 (SGLT2) inhibition with canagliflozin in type 2 diabetes mellitus
  1671. The effect of SGLT2 inhibition on urinary adenosine excretion in patients with type 1 diabetes
  1672. Can SGLT2 Inhibition with Empagliflozin Attenuate Cardiorenal Oxidative Stress Due to Its Antioxidant Effects?
  1673. Protective role of SGLT2 inhibition against the kidney disease
  1674. 323-OR: SGLT2 Inhibition Promotes Myocardial Ketone Utilization in the Normal and Failing Heart
  1675. SGLT2 inhibition in patients hospitalized for acute decompensated heart failure: rationale for and design of the EMPULSE trial.
  1676. SGLT2 Inhibition and Exercise for the Diabetic Right Ventricle
  1677. Newer Therapies for Diabetic Nephropathy and Their Cardiovascular Effects: SGLT2 inhibition in a kidney with reduced nephron number: modeling and …
  1678. How does SGLT2 inhibition improve heart failure?
  1679. Synthetic lethality targeting LKB1 mutant and EGFR wild type human non-small cell lung cancer cells by glucose starvation and SGLT2 inhibition
  1680. A Novel Potential of SGLT2 Inhibition: Antifibrotic Effect in Diabetes
  1681. Effects of SGLT2 Inhibition on eGFR and Glomerular and Tubular Damage Markers in Japanese Patients With Type 2 Diabetes
  1682. SGLT2 Inhibition by Canagliflozin Ameliorates Diet-induced Obesity by Promoting Intra-adipose Sympathetic innervation.
  1683. Diabetic Kidney Disease: Exploring mechanisms and outcomes of SGLT2 inhibition
  1684. Acute SGLT2 Inhibition and the Pressure Natriuresis Response in Rats with Type 1 Diabetes
  1685. SGLT2 Inhibition Is Predicted to Reduce LV End Diastolic Pressure: A Mathematical Modeling Analysis
  1686. 1127-P: SGLT2 Inhibition (SGLT2i) Mediated Urinary Glucose Excretion (UGE) Associations with Metabolic and Renal Hemodynamic Parameters
  1687. 1865-P: SGLT2 Inhibition Compared with Iso-energetic/Low-Carbohydrate Diet Reprograms Systemic Substrate Oxidation in Type 2 Diabetes
  1688. 155-LB: The Increase in Endogenous Glucose Production with SGLT2 Inhibition Is Unchanged by Renal Denervation but Highly Correlates to Urinary Glucose …
  1689. SGLT2 Inhibition With Dapagliflozin Improves Coronary Vascular Derangement in the Leptin-Deficient Ob/ob Mice
  1690. 1851-P: Renal Denervation Attenuates Endogenous Glucose Production Increase with SGLT2 Inhibition in Patients with Renal Transplant Recipients and Impaired …
  1691. SGLT2 Inhibition Ameliorates Exercise-Induced Pulmonary Hypertension (EIPH) in Heart Failure with Preserved Ejection Fraction
  1692. 1144-P: Patient Phenotypes and SGLT2 Inhibition in Type 2 Diabetes Mellitus: Insights from the EMPA-REG OUTCOME Trial
  1693. SGLT2 Inhibition Is Predicted to Increase NaCl Delivery to the Medullary Thick Ascending Limb But Not to Significantly Elevate Its Oxygen Consumption
  1694. SGLT2 Inhibition Mediates Protection from Diabetic Kidney Disease by Promoting Ketone Body-Induced mTORC1 Inhibition.
  1695. SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in …
  1696. 142-LB: Very Low Dose SGLT2 Inhibition Is as Effective as Angiotensin II Receptor Blockage for Cardiac and Renal Fibrosis in High Salt 5/6 Nephrectomized Rats
  1697. Erratum to: SGLT1 does compensate for SGLT2 inhibition [Eur Heart J Cardiovasc Pharmacother (2016) 2 (4): 256] The reference to Figure 2, segments S1 and …
  1698. Combining SGLT2 and DPP-4 Inhibition in Type 2 Diabetes
  1699. … with insulin exerts important effects on Zn2+-transporters in cardiomyocytes from insulin-resistant metabolic syndrome rats through inhibition of oxidative stress
  1700. The Hatter Cardiovascular Institute scientific meeting on SGLT2 inhibition
  1701. SGLT2 is not expressed in pancreatic alpha and beta cells and its inhibition does not directly affect glucagon and insulin secretion in rodents and humans
  1702. 492-P: A Novel Renoprotective Target of SGLT2 inhibitor: HIF-1α Inhibition and AMPK Activation in Renal Proximal Tubular Epithelial Cells

 

Related Posts

Shopping Cart
Scroll to Top